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Introduction
1INTRODUCTION
The International Association for the Study of Pain defines pain
as “an unpleasant sensory and emotional experience associated with
actual  or  potential  tissue  damage  or  described  in  terms  of  such
damage”.1 In children, even the definition of pain has been debated.2
In fact, pain experienced by infants and children often goes
unrecognized or even neglected.3 Research over the past two decades
has provided incontrovertible evidence that not only do neonates
experience pain but also that unrelieved pain has adverse long-term
consequences, including harmful neuroendocrine responses, disrupted
eating and sleep cycles, and increased pain perception during subsequent
painful experiences.4,5,6
Pain management is an essential component of care provided by
paediatric anesthesiologists. Regional anaesthesia plays an important
role in providing pain relief both in the intra-operative and post-
operative periods in paediatrics. Caudal epidural anaesthesia is the most
commonly practiced regional technique in children. The practice of
placing a caudal block before incision in general anaesthesia results in
reduced inhaled concentrations of volatile anesthetics intraoperatively.7
2Local anaesthetics are commonly used either alone or with additives
through the caudal route but the motor block produced may be a cause
of distress to children in the postoperative period.8
 Bupivacaine is a long-acting amide local anaesthetic that has
provided reliable anaesthesia and analgesia with differential motor-
sensory blockade for more than 40 years.9,10 But,  toxicity  due  to
accidental intravascular or intrathecal injections of bupivacaine resulting
in severe neurological, cardiovascular depression even leading to death
prompted studies on the mechanism of the cardiotoxic effects of local
anaesthetics and search for drugs with less cardiotoxicity.11,12
Bupivacaine is commercially available as racemic mixture of R- and
S- enantiomers. It has been shown that block of the inactivated state of
the cardiac sodium and potassium channels is stereoselective, with
R-bupivacaine being more potent than S-bupivacaine.13
In response to the problem of increased cardiac toxicity of
racemic mixtures of bupivacaine, single enantiomers were developed
and Ropivacaine is the first local anaesthetic to be prepared as a pure
S-enantiomer.14 Studies have shown that ropivacaine is less cardio and
neurotoxic than bupivacaine.14,15,16 The sensory block provided by
ropivacaine is similar to that produced by an equivalent dose of
3bupivacaine in extradural and peripheral nerve block whereas the motor
block produced by ropivacaine is slower in onset, less intense and
shorter in duration than bupivacaine.14
These features combined with decreased cardiovascular and
neurological toxicity make ropivacaine very useful in paediatric practice
especially for day case surgery which is increasing in frequency. Hence,
this study was undertaken to compare the effectiveness of ropivacaine
with bupivacaine for caudal anaesthesia in children.
Aim of the Study
4AIM OF THE STUDY
To compare 0.25% Ropivacaine and 0.25% Bupivacaine, given in
a volume of 0.75ml/kg through a single Presurgical Caudal block in
children aged 3-8 years undergoing sub-umbilical procedures in terms of
the Quality and Duration of Analgesia, Motor and Sensory block.
Caudal
anaesthesia
5CAUDAL EPIDURAL ANALGESIA
ANATOMY OF SACRUM17,18
The Sacrum is formed by the gradual fusion of the lamina of the
five sacral vertebrae. Variations of this fusion are common and are
responsible for the failure rate of caudal epidural analgesia.
The sacrum is triangular in shape, the apex below articulates with
the coccyx, while the base above has medial and lateral portions. The
medial part represents the body of the 1st sacral vertebra and articulates
with  the  corresponding  surface  of  the  body  of  the  5th lumbar vertebra.
The lateral portions (alae) represent fused costal and transverse
elements.
The anterior surface is concave and ridged at the sites of fusion
between the five sacral vertebrae (Fig. 1). Lateral to the ridges are the
large anterior sacral foramina through which the anterior primary rami
of the first four sacral nerves pass. These are formed due to the fusion
laterally of the transverse processes of the sacral embryologic segments.
There are usually four such foramina, the fifth being absent.  Local
anaesthetic solution injected into the sacral epidural space pass freely
through these foramina.
6Fig.1. Anatomy of Sacrum
7The posterior surface which is rough has greater interest for the
anaesthesiologist. It is convex and in the midline runs a bony ridge, the
median sacral crest with three or four rudimentary spinous processes.
The Sacral hiatus is a deficiency of posterior wall resulting from
failure of fusion of the lamina of the fifth sacral vertebra that
communicates with the sacral portion of the vertebral canal. This hiatus
is triangular in shape with its apex at the spine of fourth sacral vertebra.
In surface marking, it normally forms an approximately equilateral
triangle with the two posterior superior iliac spines. There are bony
prominences on the lateral margins of the space – the sacral   cornua –
which represent the inferior articular processes of the fifth sacral
vertebra. The base of the hiatus is the superior surface of the coccyx.
The posterior Sacrococcygeal ligament, a continuation of the
ligamentum flavum, is attached to the bony margin and covers the
hiatus. In some cases the apex of the hiatus is the third sacral spine, due
to the absence of the third and fourth laminae, and occasionally the
whole  of  the  bony  posterior  wall  is  deficient.  When  the  lamina  of  the
fifth sacral vertebra is present, the hiatus may be very small with a
diameter as narrow as 2mm making the introduction of a caudal needle
almost impossible.
8There are four pairs of posterior sacral foramina corresponding
with  the  anterior  ones.  The  sacral  canal  is  triangular  and  is  the
continuation of the epidural space and the dural sac, which usually
terminates at the lower border of the second sacral vertebra though
occasionally it extends below this point. The caudal epidural space
contains the sacral and coccygeal nerve roots and filum terminale and
continuation of the epidural venous plexus. Fibrous bands may be
present in the sacral epidural space dividing it into loculi which prevent
the spread of local anesthetic solutions and may result in incomplete
anaesthesia.
PHYSIOLOGICAL EFFECTS17
Local anaesthetic introduced into the epidural space blocks nerve
conduction to an extent determined by concentration and volume of the
drug injected, sensitivity of different fibre types and by the drug
employed. Although all agents tend to block preganglionic B fibres
more readily, followed by pain fibres, touch, proprioception and motor
fibres in that order when injected epidurally, there is a difference in the
selectivity for different sensory fibres. Smaller and unmyelinated  C and
A delta fibres are blocked earlier than the larger nerve fibres.
9The effects of caudal block on the cardiovascular system are
minimal except in cases of high caudal block. The blood pressure and
heart rate do not decrease significantly. Respiration is usually not
affected even in high block.
TECHNIQUE17
The sacral hiatus at the lower end of sacrum is extremely easy to
identify in infants and young children. The Sacral hiatus is relatively
more cephalad in infants and thus the distance between the sacral hiatus
and the end of dural sac is relatively short.
The lateral position is most often employed to perform a caudal
block in children. To identify the sacral hiatus, the tip of the coccyx
should be first palpated  with the left index finger applying firm pressure
to identify the coccyx and then the finger gently from side to side
proceeding in a cephalad direction. The first double bony protruberances
encountered are the two cornua of sacrum that define the sacral hiatus.
The cornua should be marked either mentally or with the skin marking
pen. The sacral hiatus can also be identified by drawing an equilateral
triangle with the line joining the two posterior superior iliac spines
forming the base and the sacral hiatus forming the apex (Fig. 2).
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                    Fig.2. Surface Anatomy
After careful skin preparation, the sacral hiatus is again identified
using firm pressure by the left index finger. Strict aseptic precautions
should be maintained. A short beveled 23 gauge needle, preferably
Crawford needle, is placed in the midline in the notch between the sacral
cornua at an angle of about 450 with the skin (first position) and directed
craniad to penetrate the sacrococcygeal ligament, at which time contact
is made with the anterior bony wall of the caudal canal(second
position)(Fig.3). The needle is then depressed almost flush with the skin
and then advanced into the sacral canal for 2 to 3 cm.
The advancement should not be higher than a line joining the
posterior superior iliac spines (S2 vertebra) since the dural sac ends
between the first and second sacral vertebrae in majority of patients and
even lower in neonates and infants. Auscultation of sound over the
caudal canal by injecting air (Oosh) or drug (Swoosh) can be done to
confirm the presence of the needle in the caudal space. After negative
aspiration for blood or cerebrospinal fluid, the appropriate amount of
local anesthetic is injected and the child is placed in supine position.
11
         Fig.3. Needle insertion
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CALCULATION OF VOLUME OF LOCAL ANAESTHETIC
FOR CAUDAL ANAESTHESIA
1. Armitage formula :19
 Sacral dermatomes – 0.5ml/kg,
 Sacral and lumbar – 1ml/kg
 Mid-thoracic – 1.25ml/kg
2. Spiegel formula:20
For upper abdominal surgery,   V= 4+ D-15/2  where V is the
volume of local anesthetic in milliliters  and D is the distance between
C7 and the sacral hiatus in centimeters.
3. Satayoshi formula:21
V= D-13 Where V is the volume of local anesthetic in milliliters
and D is the distance from C7 to the sacral hiatus in centimeters.
4. Schulte-Scheinberg and Rahlfs formula:22
 Volume in ml /spinal segment = 0.0558+ 0.09729(age in years)
5. Takasaki formula:23
     Volume in ml / spinal segment = 0.056 ( weight in kg)- 0.002
Physiology of
Pain and its
Assessment in
Children
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PHYSIOLOGY OF PAIN
Pain is a complex constellation of unpleasant sensory, perceptual
and emotional experiences and certain associated autonomic,
psychological, emotional, and behavioral responses. Untreated pain in
children, as the result of vaccinations and blood draws, surgery,
headaches or repeated painful procedures, can have long-term effects.24
NEUROPHYSIOLOGY OF PAIN25
A variety of chemical, thermal or mechanical insults can result in
the sensation of pain. A mosaic of pain receptors or nociceptors in the
body tissues ultimately project to pain centers in the brain. The
somatosensory system is subserved by different groups of afferent fibers
differentiated by their anatomy, rate of transmission and sensory
modality transmitted. The afferent fibres that relay pain information to
the dorsal horn of the spinal cord and then on to the brain include small-
diameter C-fibres and thinly myelinated A-delta fibres.
The dorsal horn is organized into fairly discrete lamellae. The
primary afferent first-order synapses (nociceptive-specific neurons) are
located in layers 1, 2 and 5 of the dorsal horn. Signals are then relayed
rostrally to the thalamus and the cortex. In addition, afferent impulses
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are carried to the brainstem, limbic system, and hypothalamus to
mediate many of the autonomic and affective component responses to
noxious stimuli. Deeper in the dorsal horn are located wide dynamic
range neurons (WDR) that appear to be important in the development of
hyperalgesia or wind-up phenomenon. These neurons may be
responsible for firing in pain syndromes that are not associated with
obvious tissue-damage as well.
DEVELOPMENTAL NEUROBIOLOGY OF PAIN
Nociceptive pathways in the periphery, spinal cord, and brain
develop in a series of stages through the second and third trimester in
humans. By 26 weeks of postconceptual age there is sufficient
maturation of peripheral and spinal afferent transmission for the late-
gestation fetus or preterm neonate to respond to tissue injury or
inflammation with withdrawal reflexes, autonomic arousal and
hormonal-metabolic stress responses. There are also changes in
responsiveness after injury or repetitive stimulation indicative of central
sensitization.26
It is important to understand that pain due to surgical procedures
not only results in an immediate nociceptive response but also results in
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changes in the nociceptive activation pathways that lead to
hypersensitivity, hyperalgesia and allodynia.27,28
ASSESSMENT OF PAIN
SELF-REPORTING TECHNIQUES
A.Visual analog pain scale (VAS):29 It is often considered to be
the gold standard for pain assessment. It is a 10cm horizontal line
defined by “no pain” on the left end and “severe pain” on the right. It is
used in older children and adolescents. The patient slides the cursor
along the ruler until it reaches the level that represents the intensity of
his pain. The other side of the ruler is graduated over 10mm and gives
the investigator a numerical measure of pain. In children, the Verbal
analog scale30 (pain rated from 0- no pain to 10- most possible pain)
may be more reliable.
B. Analogue Chromatic Continuous Scale (ACCS):31 The VAS
has been modified for smaller children to equate pain intensity with
colours in this scale. Instead of a line, the patient`s side of the scale is a
wide band of colour ranging from pink for no pain to dark red for
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maximum pain, with increasing shades of red for intermediate degrees
of pain.
C.  FACES pain  scale:32 It is useful in  children of 3 years and
above. This scale has cartoon drawings of faces from smiling to crying
with tears. This has score from 0 -5 or 0 – 10.
D. Bieri – Modified Scale:33,34 This has Line drawings of faces
from neutral to crying. This is mainly used for children more than 3
years old and has score from 0 -6 (original), 0 -5 or -10 (modified).
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E. OUCHER Scale: (Beyer)35 It is used in 3-12 years children.
This up and down scale has photographs of a child in six increasing
degrees of pain scored from 0 for the comfortable and calm face to 100
for the upset crying face.
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BEHAVIOURAL AND COMPOSITE PAIN ASSESSMENT
SCALES
1. Premature Infant Pain Profile (PIPP):36,37 This is mainly used
for Preterm and full-term neonates. Gestational age, behavioral
state, heart rate, oxygen saturation, brow bulge, eye squeeze,
nasolabial furrow are the parameters assessed in this scale. It has
0 – 21 scoring.
2. Neonatal  Infant  Pain  Scale  (NIPS):38 This is based on facial
expression, cry, breathing pattern, arms, legs, state of arousal. It is
mainly used for Preterm and full-term infants. It has 0-10 score.
3. CRIES:39 Crying, O2 saturation, Increased vital signs (Heart rate,
Blood pressure), Expression and Sleeplessness are assessed in this
scale. It is used in Full-term neonates and has a 0- 10 score.
4. FLACC:40 This  is  mainly  used  in  2  months  to  7  years  old
children. Facial expression, Legs, Activity state, Crying,
Consolability are assessed in this scale. It has 0 -10 score.
5. Children`s Hospital of Eastern Ontario Pain Scale
(CHEOPS):41 Cry, Facial expression, verbalization, torso
position, touch (affected area), Legs are assessed in this scale. It is
used in 1-7 year age group. It has 4-13 scoring system.
19
6. COMFORT Score:42 It is applicable for all ages. The indicators
assessed are alertness, calmness/agitation, respiratory response,
physical movements, heart rate, blood pressure, muscle tone,
facial tension. It has 0 -40 score.
7. Hannallah Objective Pain Scale: 43 It is a sensitive and reliable
tool in evaluating post-operative pain in children. It uses six
parameters like Systolic blood pressure, Crying, Movement,
Agitation, Posture and Verbalization of pain. It is scored from
0 – 12.
PHYSIOLOGICAL MEASURES
 Observing changes in vital signs such as heart rate, blood
pressure, respiration, oxygen saturation and sweating caused by pain
remove the subjectivity of behavioral pain scoring methods, but these
parameters may reflect changes for reasons other than pain and hence
not often used.
Pharmacology of
Bupivacaine
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PHARMACOLOGY OF BUPIVACAINE
HISTORY
It is an amide linked local anesthetic synthesized by B.A.F.
Ekenstam in 1957 and introduced into clinical practice by Talivuo in
1963.
CHEMICAL STRUCTURE44
An amino amide local anesthetic having a benzene ring
(lipophilic) at one end linked by an amide group to a tertiary amine
(hydrophilic) on the other end of the molecule. It belongs to the group of
pipecoloxylidide local anaethetics. All drugs in this group like
mepivacaine, ropivacaine, levobupivacaine possess chirality due to the
asymmetric carbon atom so that they may have optical isomers
(enantiomers). The enantiomers may vary in their pharmacokinetics,
pharmacodynamics and toxicity. Hence, administering a racemic drug
mixture is, in reality, administration of two different drugs.45
Bupivacaine is available as a racemic mixture with the S-enantiomer
less toxic than the R form.
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PHYSICOCHEMICAL PROPERTIES14
Molecular weight 288
pKa 8.1
Partition coefficient (N heptane/ buffer) 10
Potency 4
Protein binding in % 95
Fraction % non ionized at pH 7.4 17
Lipid solubility 28
MECHANISM OF ACTION
 Local anaesthetics prevent transmission of nerve impulses
(conduction blockade) by inhibiting passage of sodium ions through ion-
selective sodium channels in nerve membranes.46 They diffuse in their
uncharged base form through neural sheaths and the axonal membrane
to the internal surface of cell membrane sodium ion channels. Here, they
combine with hydrogen ions to form a cationic species which enters the
internal opening of the sodium ion channel and binds with the channel in
the inactivated-closed state. This produces blockade of the sodium ion
channel thereby decreasing sodium ion permeability and preventing
depolarization of the cell membrane.
Binding affinities of local anaesthetics to the sodium ion channels
are stereospecific thereby contributing to their differing potencies
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among the enantiomers. In addition to sodium ion channels, local
anaesthetics block voltage-dependent potassium channels but with lower
affinity. Other additional actions may include blockade of voltage-
dependent calcium ion channels (L-type most sensitive) and their action
on G-protein coupled receptors.47
Differential conduction blockade is illustrated by selective
blockade of small C fibers and small- and medium-sized A fibers, with
loss of pain and temperature and preservation of touch, proprioception
and motor function at low concentrations of local anaesthetics.
PHARMACOKINETICS44
The  onset  and  duration  of  conduction  blockade  is  related  to  the
pKa, lipid solubility and extent of protein binding of the drug. A low
pKa and high lipid solubility are associated with a long duration of
action. (Table 1)
ABSORPTION
The absorption of bupivacaine from its site of injection into the
systemic circulation is influenced by the site of injection and dosage and
use of epinephrine but the ultimate plasma concentration is determined
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by  the  rate  of  tissue  distribution  and  the  rate  of  clearance  of  the  drug.
Lipid solubility is important in the tissue redistribution as well as being
a primary determinant of the drug potency with bupivacaine being
highly lipid soluble and more potent. Protein binding will also influence
its distribution and excretion that parallels the lipid solubility and is
inversely related to its plasma concentration.
 Table – Pharmacokinetics
Elimination half life 210 min
Volume of distribution (Vdss) 73 L
Clearance (l/min) 0.47
Toxic plasma concentration >3 mics/ml
BIODEGRADATION AND ELIMINATION
 Liver is the site of metabolism. Two major factors controlling the
clearance of the amide linked local anesthetics are hepatic blood flow
and hepatic function. The principal pathways are N-dealkylation,
aromatic hydroxylation, amide hydrolysis and conjugation (ref). The
mean total urinary excretion of bupivacaine and its dealkylation and
hydroxylation metabolites account for >40% of the total anaesthetic
dose. Alpha1 acid glycoprotein is the most important plasma protein
binding site of bupivacaine.
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ADVERSE EFFECTS AND COMPLICATIONS
Systemic toxicity
This is due to an excess plasma concentration of the drug. Plasma
concentrations are determined by the rate of drug entrance into the
systemic circulation relative to their redistribution to inactive tissue sites
and clearance by metabolism. The magnitude of the toxicity depends on
dose administered, vascularity of the injection site, presence of
epinephrine in the solution and the protein binding of bupivacaine.
Central Nervous System
 Circumoral numbness is often an early symptom with
restlessness, vertigo,tinnitus, and difficulty in focusing developing later.
Further increases in the CNS concentration result in slurred speech and
skeletal muscle twitching which signals the imminence of tonic-clonic
seizures. Seizures are usually followed by CNS depression, which may
be accompanied by hypotension and apnea. The typical plasma
concentration of bupivacaine associated with seizures is 4.5-5.5mic/ml.
Hypoxia, Hypocarbia, hyperkalemia and acidosis can decrease the
seizure threshold and increase CNS toxicity. The treatment includes
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oxygenation, ventilation and benzodiazepine or barbiturates for
termination of the seizures.
Cardiovascular system
The cardiovascular system is more resistant to the toxic effects of
high plasma concentrations than is the CNS. Part of the cardiac toxicity
that results from high plasma concentrations occurs because it also
blocks the sodium channels in the heart and this block of the inactivated
state of the cardiac sodium and potassium (hKv1.5) channels is
stereospecific with R-bupivacaine, being more potent than
S-bupivacaine13. The primary cardiac electrophysiologic effect of local
anaesthetics is a decrease in the rate of depolarization in the fast
conducting tissues of Purkinje fibers and ventricular muscle.48 Action
potential and the effective refractory period are also decreased by local
anesthetics.
Accidental intravenous injection of bupivacaine may result in
precipitous hypotension, cardiac dysrhythmias like Premature
ventricular contractions, Supraventricular tachycardia, Atrioventricular
heart block and Ventricular tachycardia that may be resistant to
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conventional resuscitative measures. Cardiotoxic plasma concentrations
are 8-10 mic/ml.49
Moreover, bupivacaine depress the maximal depolarization rate of
the cardiac action potential (Vmax) by virtue of its ability to inhibit
sodium ion influx via sodium channels. This Vmax depression by
bupivacaine is considerably more than lidocaine and ropivacaine.14 In
addition, the rate of recovery from a use-dependent block is slower in
bupivacaine-treated papillary muscles. Moreover, high blood levels of
bupivacaine will prolong conduction time through various parts of the
heart indicated by prolongation of PR interval and QRS complex. It also
exerts dose-dependent negative inotropic action on cardiac muscle.
Pharmacology of
Ropivacaine
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PHARMACOLOGY OF ROPIVACAINE
GENERIC NAME   Ropivacaine Hydrochloride injection
CHEMICAL STRUCTURE14,44
 It is a member of the amino amide class, of local anesthetics.
It is chemically described as S-(-)-1-propyl-2`,6`-pipecoloxylidide
hydrochloride monohydrate. Ropivacaine belongs to pipecoloxylidide
group of local anaesthetics with a propyl group attached to the
piperidine nitrogen. However, it differs from other drugs in the group in
that they are racemic preparations, while ropivacaine is the first drug to
be available as a pure S-(-) enantiomer. The drug has the following
structural formula:
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PHYSICOCHEMICAL PROPERTIES
The drug substance is a white crystalline powder, with a chemical
formula of C17H2N2O.HCl.H2O. The pKa of ropivacaine is
approximately the same as bupivacaine (8.1) and is similar to that of
mepivacaine (7.7). However, ropivacaine has an intermediate degree of
lipid solubility compared to bupivacaine and mepivacaine determined by
the N heptane/buffer partition coefficient.
Molecular weight (base) 274
pKa 8.1
Potency 4
Protein binding in % 94
Fraction % non ionized at pH7.4 17
Partition Coefficient (N heptane/buffer) 2.9
MECHANISM OF ACTION
Ropivacaine is a member of the amino amide class of local
anesthetics and is supplied as the pure S-(-) enantiomer. Local
anesthetics block the conduction of nerve impulses by blocking the
sodium ion channels, thereby decreasing sodium ion conductance and
preventing depolarization of the cell membrane.
29
PHARMACOKINETICS44
Parameters Value
Elimination (t1/2 in min) 108
Clearance (L/min) 0.44
Vdss (L) 59
Protein Binding (%) 94
ABSORPTION
The systemic absorption of ropivacaine after caudal injection is
slow with peak plasma concentration being achieved much later than
bupivacaine. This may be due to the intrinsic vasoconstrictor property of
ropivacaine at low concentrations.
BIODEGRADATION AND METABOLISM44
Ropivacaine is metabolized in liver into 2,6-pipecoloxylidide and
3-hydroxyropivacaine by cytochrome P-450 enzymes. Both metabolites
have significantly less local anaesthetic potency than ropivacaine. About
1% is excreted unchanged in the urine. Its Clearance is higher than
bupivacaine and elimination half-time shorter.14 The higher clearance
may offer an advantage over bupivacaine in terms of systemic toxicity.
It has a lipid solubility intermediate between lignocaine and bupivacaine
and is highly bound to alpha1-acid glycoprotein.
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SYSTEMIC TOXICITY
Central Nervous System Toxicity
Ropivacaine produces similar spectrum of symptoms involving
the central nervous system like bupivacaine but the duration of
symptoms is shorter with the former. Moreover, studies have shown that
higher doses and free plasma concentrations of ropivacaine were
tolerated before symptoms were elicited. 50
Cardiovascular System Toxicity:
Cardiovascular effects are less pronounced with ropivacaine. The
very slow reversal of Na+channel blockade after a cardiac action
potential, which is a hallmark of bupivacaine, is considerably faster with
ropivacaine. In addition, the negative inotropic potency of ropivacaine
on isolated cardiac tissue appears to be considerably less than that of
bupivacaine.51,52 Studies in animals show that aggressive cardiac
resuscitation after an intentional intravenous bolus in dogs leads to
effective reversal of the toxic effects far more frequently with
ropivacaine than with bupivacaine indicating that ropivacaine is less
cardiotoxic.53
The greater safety of ropivacaine than bupivacaine may be related
both to the reduced toxicity of the single (S) - isomer and the difference
between the propyl and butyl –N- piperidine substituent. 54
Review of
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REVIEW OF LITERATURE
Manjushree Ray et al (Indian J. Anaesth. 2003). 55 The authors
compared 30 children aged 5-8 years who were scheduled for urogenital
operations and received 0.75ml/kg of either 0.25% Bupivacaine or
0.25% Ropivacaine via caudal route after induction of general
anaesthesia. They observed that the quality and duration of
postoperative pain relief (398± 23 min in group A vs 405± 18min in
group B) as measured by Hannallah pain scale did not differ
significantly between the two groups. The motor power score after two
hours was 7.1± 0.9 and 9.3± 1.0 in group A and B respectively
indicating quicker motor recovery in ropivacaine group. They concluded
that caudal ropivacaine provided effective postoperative analgesia with
less motor blockade when compared with bupivacaine.
Samia Khalil,M.D.et al (Anesthesiology 1999).56 The authors
studied 81 children of 1-10years of age who were randomly allocated to
receive caudal anaesthesia with ropivacaine or bupivacaine 0.25%
1ml/kg after induction of anaesthesia. They found that the quality and
duration of pain relief measured by Hannallah pain scale did not differ
between the two groups and  noted that none of the study children had
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complete motor power recovery (score 10) within 3 hours after
placement of the caudal block. The reflex scores and Sensory block did
not differ between the treatment groups. They also observed that there
was no difference between the two groups in mean time to first
micturition (254± 140min for bupivacaine vs 321± 164 min for
ropivacaine). They concluded that caudal ropivacaine provided reliable
postoperative analgesia with similar motor and sensory effects, and
similar time to first micturition compared to bupivacaine.
G.Ivani  et  al  (British Journal of Anaesthesia 1998).57 The
authors,  in double-blind, multi-centre study, randomly allocated 245
children aged 1-10 years undergoing elective minor surgery to receive  a
single caudal injection of 1ml/kg of either 0.25% Bupivacaine or 0.2%
Ropivacaine after induction of light general anaesthesia. The mean onset
time was similar for both the groups (10.4 ± 2.3min group R vs 9.7 ±
2.2min). The mean time to first analgesia was 233.2 min in the
bupivacaine and 271 min in the ropivacaine group that was statistically
insignificant. No motor block was seen in either group on awakening.
They observed that low concentrations and large volumes are the key to
obtaining differential block in children because of the small diameter of
the  A-delta  and  C-fibres  and  the  small  distance  between  the  nodes  of
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Ranvier. They suggested that 0.2% ropivacaine 1ml/kg is equivalent to
the same volume of 0.25% bupivacaine given through caudal route.
M.J. Da Conceicao et al (British Journal of Anaesthesia 1998).58
The authors studied 60 children aged 3-6 years who received either
0.375% ropivacaine or 0.375% bupivacaine 1ml/kg by caudal route after
induction of anaesthesia.  They observed that ropivacaine group showed
a shorter duration of motor block than the bupivacaine group
(P<0.05).There were no significant differences in Maunuksela pain
scores in the postoperative period. They summarized that caudal
ropivacaine appears to induce similar sensory block with shorter motor
block to that of bupivacaine.
 Giorgio  Ivani  MD  et  al (Paediatric Anaesthesia 1998).59 The
authors examined 40 patients aged 1-9 years undergoing elective minor
surgery who received caudal injection of either bupivacaine 0.25%
2mg/kg (group 1) or ropivacaine 0.2% 2mg/kg (group 2) after induction
of general anaesthesia and maintained with isoflurane with spontaneous
breathing. The mean onset of block was 12 ± 2min for group1 and 9 ± 1
min for group 2(P<0.05). The quality and duration of analgesia was
superior in group 2 (520 min in group 2 vs 253min in group1) whereas
there was no motor block at awakening in either group and no side
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effects were noticed. They observed that 2mg/kg of 0.2% ropivacaine is
sufficient to obtain a sensory block level of T7 that gave superior
analgesia than bupivacaine.
Giorgio Ivani MD et al(Can. J. anesth. 1999).60 In a prospective
double blind study, the authors studied 28 infants aged 1-12 months
undergoing elective major abdominal surgery who received after
induction of general anaesthesia either 0.7ml/kg bupivacaine 0.25%
(group B) or ropivacaine 0.2% (group R) via lumbar epidural block. The
duration of analgesia was 491 ± 291min (group R) and 456 ± 247 min
(group B). They concluded that the similar onset and duration of
0.7ml/kg of 0.2% ropivacaine and 0.25% bupivacaine suggests that
ropivacaine in children seemed to be more potent than bupivacaine and
is safe and effective for pediatric regional anaesthesia.
G.Luz  et  al (Paediatric Anaesthesia 2000).61 The investigators
compared the analgesic efficacy and degree of motor block induced by
ropivacaine 0.1% (R0.1) and 0.2% (R0.2) with bupivacaine 0.2% (B0.2)
after caudal anaesthesia in children. They observed that the duration of
analgesia (median/range) was significantly shorter in group R0.1
(1.7/0.2-6h) than in group R0.2 (4.5/1.7-6h) or group B0.2 (4/1-6h) with
a P<0.05. They also observed that the motor block in the first 2 hours
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postoperatively was significantly less for both ropivacaine groups
compared with bupivacaine (P<0.05).  They concluded that 0.2%
ropivacaine provides similar pain relief to 0.2% bupivacaine and less
motor block than bupivacaine in the early postoperative period.
Christian Breschnan et al (Paediatric Anaesthesia 2005).62 The
authors compared 182 children aged 1-7years undergoing inguinal
hernia repair or orchidopexy who received 0.2% concentration , 1ml/kg
of either  levobupivacaine (group L) or ropivacaine (group R) or
bupivacaine (group B) via caudal route. They found that the motor block
was significantly less in group R and L than in group B with no
significant difference in postoperative analgesia between them. They
concluded that during the first 2 hours postoperatively, the degree of
motor block was significantly less with ropivacaine and levobupivacaine
than with bupivacaine.
G.  Ivani  MD  et  al (Pediatric Anesthesia 2005).63 The authors
compared 0.2% ropivacaine with 0.25% levobupivacaine in 60 children
aged 1-7 years scheduled to undergo minor surgery when administered
through caudal block after induction of anesthesia. The median onset
time was 8min and 7 min for the R and L groups respectively. The
median time to first analgesic demand was 380 and 308 min in
36
ropivacaine and levobupivacaine groups, respectively. They concluded
that 0.2% concentrations of ropivacaine or levobupivacaine are
clinically very similar with regard to postoperative analgesia and
postoperative motor blockade in children undergoing sub-umbilical
surgery.
Pablo  M.  Ingelmo MD et  al (Pediatric Anesthesia 2006). 64The
authors investigated 90 children aged 1-7 years scheduled for inguinal
hernia repair or orchidopexy under propofol anesthesia who received a
caudal block with 1ml/kg of 0.2% bupivacaine, 0.2% ropivacaine or
0.2% levobupivacaine. They observed that the proportion of children
with an effective caudal block during surgery was significantly higher in
patients receiving levobupivacaine and bupivacaine compared with
those receiving ropivacaine. But there were no significant differences
between groups in the time from caudal injection to the first
administration of analgesic medication (2 ± 0.7h in bupivacaine group, 2
± 0.4h in levobupivacaine group, 2 ± 0.8h in children receiving
ropivacaine  with P=0.7). They also observed that there were no
statistical differences between groups on the incidence and intensity of
residual motor blockade at wake up or 3h after the local anesthetic
injection. They concluded that when combined with propofol anesthesia
37
without volatile anesthetics, 0.2%levobupivacaine and 0.2%
bupivacaine are more effective during surgical stimulation than
0.2%ropivacaine for caudal use with no difference in the analgesic onset
times, residual analgesia or residual motor blockade.
H.  Wulf  et  al (Anaesthesia 2000). 65 The authors evaluated the
pharmacokinetics of 1ml/kg 0.2% ropivacaine in 25 infants and toddlers
after caudal epidural injection. Mean (S.D.) Peak Plasma concentrations
of ropivacaine were 0.73(0.27) in infants and 0.49 (0.21) µg/ml in
toddlers and there were no signs of local anaesthetic toxicity. They
observed that maximum plasma concentrations occurred after a median
(range) period of 60(15-90) min and 52.5 (30-120) min in infants and
toddlers respectively. They concluded that from a pharmacokinetic point
of view caudal blockade with 0.2% ropivacaine 1ml/kg can be regarded
as a safe dose in children.
K.Knudsen et al (British Journal of Anaesthesia 1997).66 The
authors compared the incidence of CNS symptoms and changes in
echocardiography and electrophysiology during i.v. infusions of
ropivacaine, bupivacaine and placebo. Acute tolerance of i.v. infusion of
10mg/min was studied in a crossover, randomized, double-blind study in
12 volunteers previously acquainted with the CNS effects of lignocaine.
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The maximum tolerated dose for CNS symptoms was higher after
ropivacaine in nine of 12 subjects and higher after bupivacaine in three
subjects. The maximum tolerated unbound arterial plasma concentration
of bupivacaine was twice as high after ropivacaine. The time to
disappearance of all symptoms was shorter after ropivacaine (P<0.05).
Bupivacaine increased QRS width during sinus rhythm compared with
placebo and Ropivacaine. Bupivacaine also reduced both left ventricular
systolic and diastolic function compared with placebo while ropivacaine
reduced only systolic function.
Raafat S. Hannallah,M.D., et al (Anesthesiology 1987)43
evaluated 44 children aged 1.5-12 years scheduled for ambulatory
orchidopexy under caudal analgesia and ilioinguinal /iliohypogastric
nerve blocks for postoperative analgesia using a scoring system that
included Blood pressure, crying, movement, agitation, posture,
complains of pain that were scored from 0-2.
Wolf  AR  et  al  (Anesthesiology 1988)67  compared different
concentrations of bupivacaine for caudal block in 114 children aged
6months to 10 years undergoing elective surgeries like orchidopexy,
hernia repair, urethroplasty and Circumcision. They selected a volume
of 0.75ml/kg of bupivacaine for caudal block based on the calculation of
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0.056ml/kg/segment for 13 spinal segments to be blocked and found that
this volume provided adequate analgesia and similar duration of block
for both superficial abdominal and genital surgeries in infants and
children.
Pradipta Bhakta et al (Indian J. Anaesth. 2007).68  The authors
evaluated the efficacy of intranasal normal saline (group 1) and
intranasal midazolam in doses of 0.2 (group 2) and 0.3 mg/kg (group 3)
intranasally in 45 children aged 2-5 years, scheduled for minor elective
surgery.   A statistically  significant  change  in  the  level  of  sedation  was
found at 5 minutes in group2 and at 10 min in group 3. They concluded
that intranasal midazolam in a dose of 0.2mg/kg is an effective
premedication for producing effective sedation and anxiolysis in
paediatric patients without any untoward side effect.
Materials and
Methods
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MATERIALS AND METHODS
This was a Prospective Double blinded Randomized Comparative
Study conducted in Government Stanley Hospital, Chennai from April
2010 to September 2010. After obtaining clearance from the
Institutional Ethics Committee of the Stanley Medical College,
Chennai-1,  the study was explained in detail  to the parents  and written
Informed Consent was obtained from them.
Sixty children satisfying the selection criteria were randomized by
computer generated randomization table into two groups of thirty each –
Group B and Group R. The randomization sequence was prepared in
double-blinded cancelled manner. The study solution was prepared by a
final year post-graduate student who was not associated with the study.
The caudal block was performed by an assistant professor whereas the
observations were done by the author. The study blinding was broken
after the statistical analysis.
The children in group B received 0.75ml/kg of 0.25%
Bupivacaine (0.5% solution diluted in equal volumes of distilled water)
whereas those in group R received 0.75ml/kg of 0.25% Ropivacaine
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(0.5% solution diluted in equal volumes of distilled water) through the
caudal route.
CRITERIA FOR PATIENT SELECTION
The criteria for including the children in the study were:
? Age 3-8 years
? Male or Female
? ASA I or II physical status
? Elective lower abdominal or urologic surgeries like
Herniotomy, Orchidopexy, Processus vaginalis sac ligation
(PVSL), Circumcision and Urethroplasty
EXCLUSION CRITERIA
The children with the following problems were excluded from the
study:
? Local infection in the Caudal region
? Pre-existing Neuromuscular disease
? Congenital anomaly of the lower back
? Mental retardation, Delayed development
? Bleeding diathesis
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MATERIALS
The materials that were used for the study include
? 22G Hypodermic needle
? 0.25% Bupivacaine and 0.25% Ropivacaine
? Appropriate size intravenous canulae and I.V. fluids
? Drugs for General Anaesthesia
? Appropriate size Endotracheal tubes
? Other Airway equipments
? Paediatric Breathing Circuit
? Monitors, Working Suction
? All Emergency drugs
STUDY METHODS
The children were fasted for 6 hours for solids and 2 hours for
clear liquids. All children were premedicated with Intranasal Midazolam
0.2mg/kg68 15-20 min before surgery. They were brought into the
operation theatre and intravenous access was secured with appropriate
size intravenous canula. Maintenance infusion was started with Isolyte-P
(4-2-1 rule) 69 and Inj. Atropine 0.02mg/kg i.v. was given.
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Standard Monitors like Pulse Oximeter, Blood pressure, ECG,
Temperature probe, Precordial stethoscope were placed and baseline
values recorded. Then the children were pre-oxygenated with 100%O2
for 3 minutes and induced with Inj. Propofol 2.5mg/kg i.v. After
administering Inj. Atracurium 0.5 mg/kg i.v., the children were mask
ventilated with N2O:O2 (3:3) and 2% Sevoflurane mixture for 3 minutes.
Under direct laryngoscopy with the appropriate size laryngoscope blade,
orotracheal intubation was performed with the appropriate size
endotracheal tube and the tube position confirmed by capnography and
tube secured.
PROCEDURE
The children were then placed in left lateral position and under
sterile aseptic precautions, a sterile 22G hypodermic needle was
introduced in Caudal epidural space and after confirming the space, 0.75
ml/kg of either 0.25% Bupivacaine or 0.25% Ropivacaine was
administered slowly. To detect and avoid an inadvertent intravascular or
subarachnoid injection, the syringe was repeatedly aspirated and the
local anaesthetic was injected in increments while watching vital signs
and the ECG monitor. Then the patients were placed in supine position
and anaesthesia was maintained with Nitrous Oxide and Oxygen
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mixture (4:2), 1% Sevoflurane and top-up doses of Inj. Atracurium
(0.1mg/kg). The incision was made 10 min after caudal block.
An independent blinded Observer (the author) recorded heart rate
and Blood pressure, Oxygen saturation just before and after surgical
incision and then every 5 min interval till the end of surgery. If the
patient responded to the incision with a greater than 15% increase in
Systolic  Blood  pressure  or  Heart  rate,  Inj.  Fentanyl  1  µg/kg  i.v.  was
administered. Significant bradycardia was defined as greater than 20 %
decrease from baseline and significant hypotension requiring treatment
was defined as more than 20% fall of Systolic blood pressure from
baseline. At the end of the surgery, residual neuromuscular blockade
was reversed with Inj. Neostigmine 0.05mg/kg i.v. and Inj. Atropine
0.02mg/kg i.v. and the child was extubated awake. The child was then
shifted to the recovery room for Observation.
POST-OPERATIVE PERIOD
      Post-operatively, apart from monitoring Pulse rate, Systolic Blood
Pressure and oxygen saturation, the following parameters were assessed:
A. Quality of Analgesia was assessed by Hannallah Objective Pain
Scale43 every 15 min for the first two hours and every 30 min for
the next 8 hours.
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Hannallah Objective Pain Scale (OPS)
No Observation Criteria Points
1. Systolic Blood
pressure
+ 10% pre op
> 20% pre op
> 30% pre op
0
1
2
2. Crying no crying
Crying responding to tender
loving care
Crying not responding to tender
loving care
0
1
2
3. Movement none
Restless
Thrashing
0
1
2
4. Agitation asleep/calm
 Mild
 Hysterical
0
1
2
5. Posture no special posture
 Flexing legs and thighs
 Holding groin
0
1
2
6. Verbalisation of
Pain
asleep/states no pain
Vague/Can`t localize
Can localize pain
0
1
2
B. The Time between the caudal block and administration of the first
rescue analgesic drug was noted. Diclofenac rectal suppository
1mg/kg70 was given as rescue analgesic when the pain score
equals or exceeds 4.
C. Motor power was assessed by Motor power scale every 15 min
for the first two hours and every 30 min for the next eight hours.
The time of attaining full motor recovery (Score = 10) was noted.
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Motor power scale
1. Muscle Tone Flaccid
0
Hypotonia
1
Normal
2
Muscle
Power(Flexion)
Unable Partial Normal
2. Ankle 0 1 2
3. Knee 0 1 2
4. Thigh 0 1 2
5. Ability to stand 0 1 2
D. Level of Sensory block was assessed by Pin-prick test every 15
min interval till the patients regained complete sensory recovery.
E. The time to first micturition and any adverse events or
complications were noted.
STATISTICAL ANALYSIS
Data was expressed as mean ± standard deviation. Quantitative
analysis was compared with Independent sample student`s t-test for
continuous variables; Chi-square test with Yates correction was used for
discrete variables like sex, types of surgery. When using the above
statistical tests to compare the mean among the two groups, a p-value of
less  than  or  equal  to  0.05  was  taken  as  significant.  All  analyses  were
done using SPSS version 11.5 statistical software. All values were
rounded off to a maximum of two decimals.
Observation and
Results
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OBSERVATIONS AND RESULTS
DEMOGRAPHIC VARIABLES
Age Distribution among Groups R and B
Of the 30 children in group R, 21 were between 3-5 years of age
as against 23 children in group B with a minimum age of 3 years and a
maximum of 8 years in both the groups. The mean age was similar,
being around five in both groups, with no significant difference between
them. (Table 1)
Table -1
Variable
Group R Group B
P-value S.E.D.
C.I.  difference
95%
Mean SD Mean SD Lower Upper
Age (years) 4.93 1.82 4.83 1.82 0.83* 0.47 -0.84 1.04
Weight (kg) 14.13 3.00 14.07 3.96 0.94* 0.91 -1.75 1.88
Height (cm) 111.73 5.79 111.63 6.43 0.95* 1.58 -3.06 3.26
* Not Significant : S.E.D.  Standard Error of Difference   C.I. Confidence Interval
Weight and Height Distribution among Groups R and B
All children except two in group R and one in group B weighed
less than 20 kg. The least weight in group R was 10 kg compared to 9 kg
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in group B. The average weight in both the groups was around 14 kg
with no significant difference.
In  group  R,  5  children  were  taller  than  120  cm  as  against  3  in
group B with shortest being 104cm and 103 cm respectively. The mean
height was 111.73cm in group R and 111.63cm in group B, the
difference being statistically not significant (Table 1).
Gender Distribution among Groups R and B
Among the 30 children in Group R, 28 were boys and 2 were girls
whereas  in  Group  B,  27  were  boys  and  3  were  girls.  There  was  no
significant difference between two groups in terms of gender
distribution.
Group - R
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DURATION OF SURGERY
The shortest duration of surgery in both the groups was 20 min
whereas the longest was 55 min in group R and 60 min in group B. The
mean duration of surgery was 32.67 ± 10.06 min in group R and 32.83±
9.62 min in group B, the duration being comparable between the two
groups.
Duration
of surgery
Group R Group B
P-value S.E.D.
C.I. diff 95%
Mean SD Mean SD Lower Upper
Time (min) 32.67 10.06 32.83 9.62 0.95* 2.54 -5.26 4.92
* Not Significant
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TYPE OF SURGERY
Of the 60 children, 17 children in each group underwent surgeries
involving thoraco-lumbar dermatomes that required a maximum level of
T10 whereas the remaining 36 surgeries of both groups involved the
sacral dermatomes. In group R, one case of hamartoma thigh and one
case of rectal polyp were present in the others category compared to 1
case of anoplasty and 2 cases of foreign body granuloma in the lower
limbs that were present in the group B.
Surgery
Group R Group B Total
N  % N  % N  %
PVSL 6 20.0 4 13.3 10 16.7
URETHROPLASTY 5 16.6 6 20.0 11 18.3
HERNIOTOMY 6 20.0 8 26.7 14 23.3
PVSL+CIRCUMCISION 3 10.0 2 06.7 05 08.3
CIRCUMCISION 6 20.0 4 13.3 10 16.7
ORCHIDOPEXY 2 06.7 3 10.0 05 08.3
Others 2 06.7 3 10.0 05 08.3
TOTAL 30 100 30 100 60 100
Chi-square 1.78 df=6   significant value =0.94 (Not Significant)
PVSL – Processus vaginalis sac ligation
There was no significant difference in the type of surgery between
the two groups.
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HEMODYNAMIC PARAMETERS
Heart rate
The mean baseline heart rate was 130.37 ± 5.86 min in group R
compared to 129.87 ± 5.68min in group B. The maximum heart rate
before incision in group R was 138 beats/min as against 140 beats/min
in group B where as that 5min after incision was 138 beats/min in both
the groups with no significant difference in their means. The intra-
operative heart rate at 5, 10, 15, 20, 25, 30 minutes were lower than the
baseline but there was no significant bradycardia recorded in any of the
children during the study. The mean heart rates at 5 min intervals up to
the completion of surgery did not differ significantly between the two
groups.
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Blood pressure
The lowest baseline systolic blood pressure in both the groups
was 98 mmHg whereas the corresponding diastolic blood pressure was
58mmHg in group R as against 56mmHg in group B with no difference
in the means.  Both the systolic and diastolic blood pressures decreased
marginally during the intra-operative period but no patient had a fall
greater than 20% from baseline values. But, both the mean systolic and
diastolic blood pressures, before incision (100.33 ± 2.47 in group R vs
100.60± 2.69 in group B) and at 5 min intervals up to the completion of
surgery did not differ between the two groups.
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Oxygen saturation
There was no significant desaturation either in the intra-operative
or postoperative periods in both the groups.
No adverse events were observed in any of the children during
 the study.
ANALGESIA
All  the  blocks  were  successful  with  none  of  the  children
responding to the skin incision with an increase in Heart rate or Systolic
Blood pressure. There was no need for supplementation with Inj.
Fentanyl intra-operatively.
Only one child in group B was given diclofenac suppository at the
end of 3 hours whereas none in group R required supplementary
analgesia during the same time period. At the end of 4 hours, 6 Children
in group R required diclofenac suppository whereas in group B,
5 children required rescue analgesia.
But by the end of 5 hours, only 18 children in group B had
received diclofenac suppository in contrast to 21 children in group R
though the difference was statistically insignificant. In group R only one
child against three children in group B did not require supplemental pain
relief  within 6 hours.  But,  all  children required rescue analgesia by the
end of 7 hours.
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HANNALLAH PAIN SCORE
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Hannallah Objective Pain Score
Time
Group R Group B
N Mean ± SD N Mean ± SD p-value
1 hour 30 0.93 ± 0.25 30 0.70 ± 0.65 0.08
2 hours 30 1.93 ± 0.25 30 2.00 ± 0.53 0.09
3 hours 30 2.43 ± 0.50 30 2.63 ± 0.67 0.48
4 hours 30 3.10 ± 0.40 30 3.10 ± 0.61 0.36
5 hours 30 3.57 ± 0.57 30 3.53± 0.82 0.83
6 hours 30 4.00 ± 0.59 30 3.87 ± 0.86 0.71
7 hours 30 4.30 ± 0.54 30 4.40 ± 0.81 0.46
8 hours 30 4.30 ± 0.47 30 4.53 ± 0.57 0.09
9 hours 30 4.40 ± 0.50 30 4.63 ± 0.62 0.11
10 hours 30 4.40 ± 0.50 30 4.53 ± 0.63 0.37
 Post-operatively, the quality and duration of analgesia did not
differ between the two groups. The Hannallah pain scores did not differ
significantly at 0,1,2,3 hours post-operatively between the two groups.
But the mean scores were slightly less in group R than in Group B after
6 hours, though they were statistically insignificant.
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Time of
first
analgesia
Group R Group B
P-
value
S.E.D.
C.I. of diff. 95%
Mean SD Mean SD Lower Upper
Time
(min)
338.83 44.75 346.67 51.06 0.53* 12.39 -32.65 16.98
* Not significant
The mean time from caudal placement to the first administration
of pain medication was 338.83 ± 44.75 min in group R and
346.67± 51.06 min in group B, the difference being statistically
insignificant (P=0.53)
MOTOR POWER RECOVERY
15 children in group R had full motor power (score =10) at the
end of 105 min after surgery whereas only 4 children had full motor
power in group B. At the end of 120 min, only one out of the total 30
children in group R did not have full motor recovery whereas 12 out of
the 30 children in group B were having mild motor weakness. All
children had regained full motor power by the end of two and half hours
in both the groups.
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Motor Power Score
Time
Group R Group B
N Mean ± SD N Mean ± SD p-value
0 Minutes 30 2.33 ± 0.48 30 2.03 ± 0.18 0.003
30 Minutes 30 3.30 ± 0.75 30 2.63 ± 0.56 0.002
60 Minutes 30 5.03 ± 0.85 30 4.13 ± 1.01 0.001
90 Minutes 30 7.80 ± 0.93 30 6.73 ± 1.05 0.001
105 Minutes 30 9.17 ± 0.95 30 8.20 ± 0.85 0.001
120 Minutes 30 9.97 ± 0.18 30 9.47 ± 0.73 0.001
150 Minutes 30 10.00 ± 0.00 30 10.00 ± 0.00 -
Immediately after surgery, the mean motor score was 2.33± 0.48
in group R as against 2.03± 0.18 in group B. Although this was
clinically not significant, it was statistically highly significant with a
P value of 0.003. The mean scores at 30min and 1 hour after surgery
were both clinically and statistically significant between the two groups
with higher scores observed in ropivacaine group.
Variable
(min)
Group R Group B P-
value
S.E.D.
C.I. of diff 95%
Mean SD Mean SD Lower Upper
Full
Motor
Recovery
113.50 10.18 128.50 17.48 0.001 3.69 -22.39 -7.61
The mean time for full motor recovery in group R was 113.50 ±
10.18 min compared to 128.50± 17.48 min in group B the difference
being highly significant (P=0.001).
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SENSORY RECOVERY
The sensory block (mean ± s.d.)  resolved completely by 77.50 ±
2.67 min in ropivacaine group and by 80.00 ± 7.19 min in bupivacaine
group, the difference being statistically not significant (P=1.49).
Variable
(min)
Group R Group B P-
value S.E.D.
C.I. of diff
95%
Mean SD Mean SD Lower Upper
FULL
SENSORY
RECOVERY
77.50 2.67 80.00 7.19 1.49* 1.67 -5.82 0.85
*not significant
TIME TO FIRST MICTURITION
 Of the 60 children, 6 in group R and 4 in group B were already
catheterized for their urethroplasty surgeries. There was a delay of at
least 6 hours in passing micturition in the remaining children. Among
others, there was no difference in the time to first micturition between
group R (326.88 ± 41.88 min) and B (330.00 ± 32.62 min). No child
required catheterization postoperatively due to retention.
Variable
(min)
Group-I Group-II P-
value
S.E.D.
C.I. of diff 95%
Mean SD Mean SD Lower Upper
Time to
first
Micturition
326.88 41.88 330.00 32.62 0.30* 10.57 -24.38 18.13
*not significant
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Postoperatively, there were no adverse hemodynamic alterations
without any significant difference in the Pulse rate, Blood pressure and
the Oxygen saturation between the two groups.
POST – OP Systolic  Blood  Pressure
Discussion
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DISCUSSION
Our study showed that a single pre-surgical caudal injection of
ropivacaine after induction of anaesthesia provided good quality
analgesia of sufficient duration following lower abdominal and perineal
surgeries.
The mean age in the two groups was comparable - around five
years with a minimum of 3 years and a maximum of 8 years. The mean
weight (around 14 kg) and height (around112 cm) were also comparable
in  both  the  groups.  All  our  study  children  were  premedicated  with
intranasal midazolam 0.2mg/kg as suggested byPradipta Bhakta et
al.68Since  the majority of the procedures were for inguinal hernia,
hydrocele, orchidopexy and phimosis, the mean duration of surgery was
short - around 32 min in both the study groups. All the children had
stable hemodynamics intraoperatively. A marginal decrease in heart rate
and blood pressure which was seen in our study could be explained by
the fall in these parameters that is usually associated with induction of
anaesthesia and a successful caudal block.
Ropivacaine has been used in different concentrations for caudal
block with varying efficacy. Da Conceicao et al58 used ropivacaine
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0.375% for caudal block and found that it produces sufficient analgesia
for lower abdominal surgery in children. But, Ivani et al57,59  in two
different studies observed that 0.2% ropivacaine given through the
caudal route in children is sufficient to provide sensory blockade for
infra-umbilical surgeries. In our study, we used 0.25% ropivacaine that
provided reliable and long duration analgesia. This finding is in
conjunction with previous studies .55,56
 We included children who underwent surgeries involving
lumbosacral (low) as well as lower thoracic (high) innervations but the
number of low and high procedures did not differ between the two
groups.  Wolf  et  al67  demonstrated that 0.75ml/kg of 0.25% or 0.125%
bupivacaine with epinephrine caused adequate sensory blockade for
high procedures involving 13 dermatomes in children. In our study, we
used 0.75ml/kg volume for caudal injection that was adequate for both
thoracolumbar as well as sacral surgeries. But, other studies19,56,59 have
used 1ml/kg of local anaesthetic for thoracolumbar surgeries.
  Many workers57,59 had observed that 1ml/kg of 0.2% ropivacaine
and 0.25% bupivacaine by caudal block  had similar onset and duration.
They compared these concentrations in order to achieve equal volumes
and to maintain blindness of the study. But, we used equal volumes of
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0.25% concentration of both ropivacaine and bupivacaine, thereby
achieving study blinding as done by Khalil et al56 and others.55
G.Ivani et al59 found  that  the  mean  onset  time  of  caudal  0.2%
ropivacaine was 9 min with that of 12 min for 0.25% bupivacaine
whereas another study57 had observed that the mean onset time was 9.7
and 10.4 min respectively. Since our aim was not to compare the onset
times, we used a fixed time of 10min after caudal block for incision for
both the groups. In our study, this was found adequate for both
ropivacaine and bupivacaine with no child requiring fentanyl
supplementation.
T.L.Ala-Kokko et al50 had evaluated that 1ml/kg of 0.2%
ropivacaine (2mg/kg) and 0.2% bupivacaine (2mg/kg) given by caudal
route in 30 children aged 2.3 to 8.7 years resulted in peak plasma
concentrations of 1.22 µg/ml and 1.28 µg/ml respectively which is much
less than the maximum tolerated venous concentrations of ropivacaine
(2.2(0.8) and bupivacaine (2.1 +-1.2) in adult volunteers.15 They also
observed that the time taken to achieve peak concentrations were
significantly longer for ropivacaine than bupivacaine indicating slower
absorption  and  tissue  distribution   of  the  former  after  caudal
administration. This difference may be due to the intrinsic
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vasoconstrictor effect of ropivacaine at low concentrations and higher
lipid solubility of bupivacaine. In our study, we used 0.75ml/kg of
0.25% ropivacaine, i.e.1.875 mg/kg of ropivacaine that is much less than
that used in the above study. This obviated the need for measuring
plasma concentration in our study.
In our study, the mean time from caudal block to first dose of
diclofenac administration was comparable for both the groups with the
average  being  slightly  less  than  6  hours.  A  similar  trial56 using
0.25% bupivacaine or 0.25% ropivacaine showed that postoperative
analgesia  was  required  at  a  mean  time  of  11hours  for  both  drugs
whereas another study58 using 0.375% bupivacaine or ropivacaine
revealed that the mean time for first analgesia was around 5 hours in
both  drugs.  On  the  contrary,  Ivani  et  al59 compared 0.2% ropivacaine
with 0.25% bupivacaine and observed that first requirement of rescue
analgesia was 253 and 520 min for bupivacaine and ropivacaine groups
respectively(P<0.05). But this finding was not replicated by other
studies.55,56,57
Our study showed that significant motor block was demonstrated
in all our study children in the recovery room, with the ropivacaine
group having a statistically significant greater motor power score than
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bupivacaine group. This faster resolution of motor blockade in the
ropivacaine group continued in the post-operative ward also. This is in
conjunction with other studies55 that recorded quicker motor recovery
with 0.25% ropivacaine than 0.25% bupivacaine. Khalil et al56 also
found delayed motor recovery in both the groups and found that those
who received 0.25% ropivacaine had slightly higher mean motor score
at the end of 3 hours than those who had received 0.25% bupivacaine.
Da Conceicao et al58used a higher concentration (0.375%) of
ropivacaine and bupivacaine and observed that there was significant
difference between ropivacaine and bupivacaine groups in motor block
postoperatively with lesser blockade in the former. This quicker motor
recovery in ropivacaine group may be due to its less lipid solubility as
determined by the N-heptane/buffer partition coefficient of 2.9 as
against that of 10 for bupivacaine.14 This low lipid solubility and high
pKa (8.1) of ropivacaine causes blockade of A – delta and C fibers
supplying pain and touch sensation to a greater extent than that of the
A-? and A-? fibers supplying motor sensation.
Other workers55,56 had observed that there were no significant
differences in the quality or duration of sensory blockade between equal
doses and concentrations of bupivacaine and ropivacaine and reported
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that sensory block resolved earlier than motor block. Our study also
supported their views.
In our study, there was a delay in micturition of around five and
half hours in both the groups with no significant difference between
them. This was supported by others56 who did not find any difference in
the time to first micturition between ropivacaine and bupivacaine. This
delay may be due to the blockade of the sacral fibres caused by caudal
block that prevents voiding of urine.
Only one child in ropivacaine and 2 children in bupivacaine group
had vomiting postoperatively that was treated with Inj. Ondansentron
0.01mg/kg i.v. This may be due to the effects of general anaesthestics.
Due to the smaller study group, we did not encounter any instance
of intravenous or intraosseous injections that could have resulted in local
anaesthetic toxicity, thereby conferring an added advantage for
ropivacaine in terms of increased safety profile.
Our study and others56,57,59 have compared the effects of caudal
ropivacaine and bupivacaine when administered along with volatile
anaesthetics intraoperatively. Pablo M. Ingelmo et al64 in their study
observed that without the effects of volatile anaesthetics,
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0.2% ropivacaine is less effective during surgical stimulation than
0.2% bupivacaine and 0.2% levobupivacaine when used for caudal
block. They reasoned out this finding based on the observation that all
volatile anaesthetics depress the spinal alpha-motor neuron activity and
may potentiate caudal ropivacaine. But they too observed that there was
no difference in the analgesic onset times or residual analgesia
indicating ropivacaine is an effective local anaesthetic.
Summary
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SUMMARY
Bupivacaine is the most frequently used local anaesthetic for
caudal anaesthesia in children that provides reliable and long-lasting
anaesthesia and analgesia. Ropivacaine provides pain relief similar to
bupivacaine with less motor blockade and being a pure S-enantiomer is
less cardiotoxic than the latter.
The aim of the study was to compare Caudal Ropivacaine 0.25%
and caudal Bupivacaine 0.25% in terms of the quality and duration of
analgesia, motor and sensory block for sub-umbilical surgeries.
In  a double-blinded comparative study, 60 children aged 3-8
years of ASA I or II physical status were randomly allocated to receive a
single presurgical caudal injection of 0.75ml/kg of either 0.25%
Ropivacaine (Group R) or 0.25% Bupivacaine (Group B) after induction
of general anaesthesia. Apart from monitoring the vital parameters, all
children were assessed for postoperative analgesia by Hannallah pain
scale and for motor blockade by Motor power score. The time for full
sensory recovery was also observed.
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The groups were comparable for age, sex, weight, height, vital
signs, duration and type of surgery. The quality and duration of
postoperative pain relief did not differ between the two groups (338.83 ±
44.75 min in group R Vs 346.67 ± 51.06 min in group B). The motor
blockade was significantly less in ropivacaine group than in bupivacaine
group with quicker motor recovery recorded  in group R(113.50 ± 10.18
min) than group B(128.50 ± 17.48 min) with a P<0.001. The time for
full sensory recovery was similar for both the groups (77.50 ± 2.67 min
in group R vs 80.00 ± 7.19 min in group B). Postoperative vitals were
stable in all the children and the time to first micturition did not differ
between the two groups (326.88 ± 41.88 min in R vs 330.00 ± 32.62 min
in B). No adverse events occurred during the study.
Ropivacaine is a safe and effective local anaesthetic for paediatric
caudal anaesthesia. Ropivacaine 0.25% 0.75ml/kg provided good quality
and adequate duration of analgesia similar to bupivacaine in equal
volumes and concentration when administered for caudal block for sub-
umbilical surgeries. Ropivacaine produced significantly faster motor
recovery than bupivacaine giving a distinct advantage over the latter by
allowing the children to be discharged earlier.
Conclusion
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CONCLUSION
In conclusion, Caudal Ropivacaine 0.25%, 0.75ml/kg provided
reliable and long lasting analgesia similar to 0.75ml/kg of 0.25%
Bupivacaine in children undergoing sub-umbilical surgeries.
Ropivacaine caused less motor blockade than bupivacaine with similar
time for sensory recovery. These along with the lower intrinsic toxicity
of ropivacaine make it an effective and safe drug for day case surgery in
paediatric patients.
Annexure
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úSôVô° RLYp Rôs
ÏZkûRLÞdLô] LôPp l[ôd¡p (Caudual Block) úWô©úYúLnu
Utßm ×©úYúLnu UVdL UÚkÕLû[ Jl©Óm BnÜ
úSôVô°LÞdLô] RLYp :
BWônf£«u úSôdLØm, BRôVeLÞm :
EeLs ÏZkûRûV DÓTÓjR §hPªPlThÓs[ CkR UÚjÕY
BWônf£ BnYô]Õ. 0.25% úWô©úYúLnu ApXÕ 0.25% ×©úYúLnu
UVdL UÚkÕLs ÏZkûR«u ØÕ¡p £ß F£ êXm ùNÛjRlThÓ AR]ôp
HtTÓm Y­ ¨ YôWQm úTôu\ Ï±ÂÓLû[ Jl©hÓl TôolTûR úSôdLUôL
ùLôiÓs[RôÏm. UÚjÕY ®YWd ûLúVh¥p A±®dLlThÓs[
BnÜL°u T¥, úWô©úYúLnu UÚkÕ ×©úYúLnu UÚkûR®P Ïû\Yô]
CÚRV Tô§lûTúV HtTÓjÕ¡\Õ. úUÛm CÕ ÏZkûRûV ®ûWYôL SPUôP
ûYdL ERÜ¡\Õ. CkR UÚkÕ ÏZkûRL°p TôÕLôlTô]RôLÜm CÚlTRôL
A±VlTÓ¡\Õ. CmUÚk§]ôp EeLs ÏZkûR TV]ûPYôoLs G]
G§oTôodLlTÓ¡\Õ. CkR Bn®u êXm ùT\lTÓm A±Yô]Õ, CÕ úTôu\
AßûY £¡fûN ùNnÕ ùLôsÞm Ut\ ÏZkûRLÞdÏm TVàûPVRôL
AûUÙm.
Uôtß UVdL UÚkÕLs:
LôPp l[ôd¡p úWô©úYúLnu Utßm ×©úYúLnu UÚkÕLs
ApXôUp ­dú]ôúLnu úTôu\ UÚkÕLÞm ETúVôLj§p Es[]. CÕ
úUtÏ±l©hÓs[ CWiÓ UÚkÕLû[ ®P Ïû\Yô] úSWúU Y­ ¨ YôWQm
A°dÏm.
Uôtß UVdL Øû\Ls :
CÕ úTôu\ ùRôl×ÞdÏ ¸úZ ùNnVlTÓm AßûY £¡fûNdÏ
(ÏP­\dLm, ®ûW¿o úLôojÕRp, ®ûW C\eLôUp CÚlTÕ úTôu\Yt±dÏ
AßûY £¡fûN ùNnYÕ) ùYßm ØÝ UVdLúU Øu]ôp ùLôÓdLlThÓ
YkRÕ. CkR Øû\«p Y­ ¨YôW¦Lû[ CWjR Sô[j§u êXUôL
ùLôÓlT§]ôp HtTPd á¥V êfÑ ®ÓY§p £WUm Utßm úTô§V Y­
¨YôWQm CpXôRÕ úTôu\ £WUeLs Es[].
EiPôLdá¥V CPoLs :
Aû]jÕ UVdL UÚkÕ Utßm UVdL Øû\LÞPu CÚlTÕ
úTôXúY CkR Øû\«Ûm £X G§oTôWô CPoLs SûPùT\Xôm. LôPp
l[ôd Øû\«p ªL A¬RôL CkR UVdL UÚkÕLs CWjR§XúXô ApXÕ
GÛm×LÞdÏsú[ô ùNÛjRlTÓYRtLô] Yônl× Es[]. AlT¥VôL úSÚm
ThNj§p, AÕ CÚRV Tô§lûTÙm HtTÓjRXôm. CkR UÚkÕL°]ôp JÚ
£X úTÚdÏ AßûY£¡fûNdÏl ©u Yôk§ ApXÕ £ß¿o L¯lT§p RôURm
úTôu\ £ß ©WfNû]Ls HtTP Yônl×s[Õ.
CkR FßLû[ Ïû\dÏm ùTôÚhÓ UÚjÕYWôp ùNnVlTÓm
ùTôÚjRUô] áokRôWônÜ úNôRû]Ls Utßm Øuù]fN¬dûL
SPY¥dûLLÞPu CkR BnûY Y¥YûUdL AdLû\ GÓjÕd
ùLôs[lThÓs[Õ. BnÜ ùTôÚlúTtßs[ UÚjÕYo, CkR BnÜ
UÚkÕLÞPu ùRôPo×ûPV Ut\ Aû]jÕl ©\ CPoLû[l Tt±Ùm
EeLÞdÏ ®[dÏYôo.
BnÜ SûPØû\Ls :
CkR Bn®p, EeLs ÏZkûRdÏ AßûY £¡fûNdÏ ùNpÛm
Øu çdLUÚkÕ ùLôÓjÕ Aû\dÏ GÓjÕf ùNôpXlTÓYôoLs. AeÏ
CWjR Sô[j§p £ß F£ êXm ØÝ UVdLm Utßm ØfÑd ÏZô«p £ß
¥ël (Endotracheal Tube) êXm ùNVtûL ÑYôNm ùLôÓdLlTÓm. ©\Ï
EeLs ÏZkûRL°u ØÕ¡p, £ß F£ êXm Bn®u UÚkÕLs
(úWô©úYúLnu ApXR ×©úYúLnu) ùNÛjRlThÓ AßûY £¡fûN
ùNnVlTÓm. £¡fûNdÏ©u ÏZkûRûV UVdLj§p CÚkÕ ùY°úV
ùLôiÓ YWlThÓ êfÑd ÏZô«p CÚkÕ ¥ël GÓdLlTÓm. AßûY
£¡fûNdÏl©u EeLs ÏZkûR«u Y­, EQof£«u A[Ü Utßm
RûNLû[ CVdÏm §\u B¡VûY T¬úNô§dLlTÓm. EeLs ÏZkûRdÏ
Y­ HtThPôp ARtLô] Y­ ¨YôW¦ ùLôÓdLlThÓ ùRôPokÕ EeLs
ÏZkûR UÚjÕYWôp LiLô¦dLlTÓm.
Bn®p EeLs E¬ûULs :
EeLs UÚjÕYl T§úYÓLs ªLÜm AkRWeLUôL ûYjÕd
ùLôs[lTÓm. CkR Bn®u Ø¥ÜLs A±®Vp Tj§¬dûLL°p
©WÑ¬dLlTPXôm. B]ôp, ùTVûW ùY°«ÓYÕ êXm EeLs ÏZkûR
AûPVô[m LôhPlTPUôhPôoLs. CkR Bn®p EeLs ÏZkûR«u TeúLt×
Ru²fûNVô]Õ Utßm LôWQeLs GûRÙm á\ôUúXúV ¿eLs CkR
Bn®­ÚkÕ GkR JÚ úSWj§Ûm ®X¡d ùLôs[Xôm. GlT¥«ÚkRôÛm
EeLs ÏZkûRdÏ RÏkR UVdL UÚkÕ ùLôÓjÕ AßûY £¡fûN
ùNnVlTÓm. CkR Bn®p HúRàm TdL ®û[ÜLs HtThPôp EeLs
ÏZkûRdÏ ØÝ £¡fûN UÚjÕY ÏÝ®]Wôp A°dLlTÓm.
Sôs : ùTtú\ôo ûLlùVôlTm/
CPÕ ùTÚ®Wp úWûL
BWônf£ ¨ûXVm : AWÑ vPôu­ UÚjÕYUû],
ùNuû] - 600 001.
TeÏ ùTßm ÏZkûR«u ùTVo :    YVÕ :
TeÏ ùTßm ÏZkûR«u Gi :    Tô­]m : Bi  ùTi 
ùTtú\ôo ùTVo/ ®XôNm :
ùTtú\ôo CRû] (P) Ï±dLÜm.
úUúX Ï±l©hÓs[ UÚjÕY Bn®u ®YWeLs G]dÏ ®[dLlThPÕ.
GuàûPV NkúRLeLû[ úLhLÜm. ARtLô] RÏkR ®[dLeLû[ ùT\Üm
YônlT°dLlThPÕ.
Sôu Gu ÏZkûRûV CqYôn®p Ru²fûNVôLRôu TeúLtL
ûYd¡ú\u. GkR LôWQj§]ôúXô GkR LhPj§Ûm GkR NhP £dLÛdÏm
EhTPôUp Gu ÏZkûRûV CqYôn®p CÚkÕ ®Xd¡ ùLôs[Xôm Gußm
A±kÕ ùLôiúPu.
CkR BnÜ NmTkRUôLúYô, CûR NôokR úUÛm BnÜ úUtùLôsÞm
úTôÕm CkR Bn®p TeÏùTßm UÚjÕYo Gu ÏZkûRÙûPV UÚjÕY
A±dûLLû[ TôolTRtÏ Gu AàU§ úRûY«pûX G] A±kÕ
ùLôs¡ú\u. Gu ÏZkûRûV Bn®p CÚkÕ ®Xd¡d ùLôiPôÛm CÕ
ùTôÚkÕm G] A±¡ú\u.
CkR Bn®u êXm ¡ûPdÏm RLYpLû[Ùm, T¬úNôRû]
Ø¥ÜLû[Ùm Utßm £¡fûN ùRôPoTô] RLYpLû[Ùm UÚjÕYo
úUtùLôsÞm Bn®p TVuTÓj§d ùLôs[Üm AûR ©WÑ¬dLÜm Gu
ØÝ U]ÕPu NmU§d¡uú\u.
CkR Bn®p Gu ÏZkûRûV DÓTÓjR ØÝU]ÕPu Jl×d
ùLôs¡ú\u. CkR UVdL UÚkÕLs Utßm UVdL Øû\«]ôp HtTPd
á¥V ©u ®û[ÜLs Utßm G§oTôWôR ®û[ÜLs Tt± G]dÏ ®[dLUôL
ùR¬®dLlThPÕ.
CkR Bn®p Gu ÏZkûRdÏ ØÝ UVdLm ùLôÓjR ©u ØÕ¡p
£ß F£ êXm (LôPp l[ôd) úWô©úYúLnu ApXÕ ×©úYúLnu UVdL
UÚkÕLû[ ùLôÓdL NmUj§d¡ú\u. úUÛm,AßûY £¡fûNdÏl ©u
ÏZkûR«u Y­, EQof£«u A[Ü Utßm CÓl×, Lôp RûNûV CVdÏm
A[Ü úTôu\ Aû]jÕ ®RUô] T¬úNôRû]Lû[Ùm ùNnÕ TôodL Sôu
ØÝU]ÕPu NmUj§d¡uú\u.
Gu ÏZkûR«u SXu LÚ§úV CkR BnÜ úUtùLôs[lThPÕ Guß
ùR¬kÕ CkR Bn®tÏ JlT°d¡uú\u.
ùTtú\ô¬u ûLùVôlTm .................................... CPm ........................ úR§
LhûP®Wp úWûL (CkR T¥Ym T¥jÕ LôhPlThÓ ×¬kÕ ûLúWûL A°d¡uú\u)
BnYô[¬u ûLùVôlTm ...................................... CPm ....................... úR§
BnYô[¬u ùTVo ...........................................................
ÑV Jl×Rp T¥Ym
BnÜ ùNnVlTÓm RûXl×
ÏZkûRLÞdLô] LôPp l[ôd¡p úWô©úYúLnu Utßm ×©úYúLnu UVdL
UÚkÕLû[ Jl©Óm BnÜ
PROFORMA
Date : Serial No.
Name :
Age/Sex : Weight : Ht : I.P. No. :
Diagnosis :
Surgery Planned :
ASA Status : Parental Consent :
Associated medical conditions : Last Oral intake :
Premedication : Intranasal Midazolam : Time :
Shifted to O.T. Time : I.V. access :
Monitors : Baseline :    HR : B.P. : SpO2 :
Induction : Propofol Atracurium
Intubation : E.T.Size :
Caudal Block time :
Volume of the Local Anaesthetic:
Incision time :
Intra-op parameters :
Time  0    5    10     15     20     25    30     35     40     45     50     55   60
HR
BP
SpO2
Intra-op complications
PROFORMA (Contd.)
Reversal :  Neo  Atropine Extubation
Recovery /Reflexes :
Duration of Surgery:
Post-OP :
1. Hannallah Pain Scale
0 15 30 45 60 75 90 105 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600
2. Motor Power Scale
0 15 30 45 60 75 90 105 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600
3. Vital Parameters
0 15 30 45 60 75 90 105 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600
PR
SBP
SP02
Time of First Analgesic drug administration :
Time of Full Motor recovery  :
Time of Full Sensory recovery :
Time for first Micturition :
Anaesthesiologist’s Signature
S. No.Group AGE SEX Wt(Kg) Ht (cm) I.P. NO. SURGERY VOL.L.A.
1 B 3.5 M 12 106 61958 R PVSL 9
2 B 3 M 9 104 61644 L IH 6.75
3 B 3 M 10 103 61965 CIRCUM 7.5
4 R 8 M 23 122 61954 RECTAL POLYP 17.25
5 R 5 M 14 110 61963 R PVSL 10.5
6 B 3 M 10 105 61960 R PVSL WITH CIRCUM 7.5
7 B 3.5 M 11 106 62012 RORCHIDOPEXY 8.25
8 R 5 M 13 114 62103 URETHROPLASTY 9.75
9 R 8 M 15 118 62099 LIH 11.25
10 B 5 M 11 112 62098 R PVSL 8.25
11 B 7 M 19 116 61964 CIRCUMCISION 14.25
12 B 3 M 9 104 62096 CIRCUM 6.75
13 R 5 M 13 115 62102 RPVSL 9.75
14 B 5 M 15 116 62101 LIH 11.25
15 R 6 M 16 116 62093 L PVSL 12
16 R 4 M 12 108 62155 URETHROPLASTY 9
17 R 3.5 M 12 106 62226 RPVSL,CIRCUM 9
18 B 3 M 10 106 62158 R PVSL WITH CIRCUMCISION 7.5
19 R 3 M 10 104 62160 CIRCUM 7.5
20 B 8 F 19 118 62157 BIL. HERNIOTOMY 14.25
21 B 5 M 14 115 62285 URETHROPLASTY 10.5
22 B 5 M 16 117 62219 RIH 12
23 B 8 M 20 120 62221 RIH 15
24 B 5 M 18 116 62291 RECTAL POLYP 13.5
25 B 3 M 11 104 62329 L PVSL 8.25
26 B 5 M 16 117 62340 R PVSL 12
27 R 4 M 13 105 62393 LIH 9.75
28 R 8 M 18 120 62059 R IH 13.5
29 B 8 M 19 122 62063 L ORCHIDOPEXY 14.25
30 R 3 M 11 104 62113 URETHROPLASTY 8.25
31 R 8 M 17 116 62115 R ORCHIDOPEXY 12.75
32 B 8 M 24 119 62116 MAGPI 18
33 R 3.5 F 14 114 62110 CLITOROPLASTY 10.5
34 B 3 M 10 102 62444 ANOPLASTY 7.5
35 R 3 M 12 110 62118 R PVSL 9
36 B 5 F 13 116 62443 RIH 9.75
37 B 5 M 14 118 62447 URETHROPLASTY 10.5
38 B 7 M 18 120 62456 RIH 13.5
39 B 4 M 13 110 62454 R ORCHIDOPEXY 9.75
40 R 4 M 12 113 62534 CIRCUM 9
41 B 3 M 12 105 62660 URETHROPLASTY 9
42 B 8 M 19 118 62450 URETHROPLASTY 14.25
43 R 3 M 13 108 62650 CIRCUM 9.75
44 B 4 M 14 108 62339 URETHROPLASTY 10.5
45 R 8 M 22 120 62702 L ORCHIDOPEXY 16.5
46 R 3 M 14 105 62652 CIRCUM 10.5
47 R 4 M 12 105 62709 R PVSL 9
48 R 5 M 13 108 62785 CIRCUM 9.75
49 B 3 M 9 103 62745 LIH 6.75
50 B 4 F 13 109 62832 HAMARTOMA 9.75
51 R 5 M 15 110 62786 RIH 11.25
52 R 3 M 12 106 62829 R PVSL WITH CIRCUM 9
53 R 6 M 15 120 62830 HYPOSPADIAS 11.25
54 B 5 M 14 114 62878 CIRCUMCISION 10.5
55 R 3.5 M 12 105 62875 R PVSL WITH CIRCUM 9
56 R 3 F 11 106 62781 RIH 8.25
57 R 6 M 15 118 62876 URETHROPLASTY 11.25
58 R 5 M 13 114 62874 R PVSL 9.75
59 R 4.5 M 14 112 62748 RIH 10.5
60 R 8 M 18 120 62880 CIRCUM 13.5
MASTER CHART - DEMOGRAPHIC - DATA
S. No. Grp BASE
BEF
INCI 5 10 15 20 25 30 35 40 45 50 55 60
1 B 138 134 132 130 126 124 122
2 B 134 132 130 128 126 124 122
3 B 130 126 125 124 122 120
4 R 125 124 122 120 121 119 118 120
5 R 126 122 120 118 119 117 116
6 B 132 130 128 129 126 124 122 120 120
7 B 136 136 134 132 130 128 126 122 120 122
8 R 118 119 116 115 114 110 112 116 118 110 114
9 R 128 126 124 122 120 118
10 B 126 124 120 118 116 114
11 B 126 122 120 118 116 114 113
12 B 138 132 130 128 126 124
13 R 122 121 120 118 116 117 115 116
14 B 126 124 122 120 119 121 120
15 R 126 122 124 120 122 123 121 118
16 R 120 120 116 114 115 116 114 115 116 118 112 114
17 R 124 120 118 116 117 115 114 116 115
18 B 138 136 132 130 131 128 129 126 124 120
19 R 126 122 120 118 116 114 116
20 B 126 124 120 118 116 118 114 115 116
21 B 124 122 120 118 119 117 115 114 115 113 114 112 113 112
22 B 126 122 120 118 117 115 116
23 B 124 122 120 118 119 116 114
24 B 130 128 126 124 125 122 120 121
25 B 140 140 138 136 134 132 130
26 B 126 126 124 120 118 118 118 116
27 R 130 128 126 124 125 122 120 118
28 R 126 124 121 120 118 116 114
29 B 128 126 124 120 118 116 116 117 115 112 110
30 R 136 134 132 130 126 122 120 118 116 114 112 113
31 R 124 120 118 116 114 112 113 110
32 B 126 124 123 121 120 118 116 113 112 110
33 R 136 134 132 130 128 126 125 124 120 122 120 121
34 B 130 128 126 124 122 123 122 120 121 120
35 R 138 136 132 130 126 122 120 118
36 B 136 134 132 130 128 126 124
37 B 126 126 125 124 120 118 116 115 112 110 108
38 B 126 124 120 119 118 116 115
39 B 128 126 124 120 119 116 114 115 114 113
40 R 136 132 130 128 126 124
41 B 126 125 124 120 118 116 116 114 115 114 112
42 B 120 118 118 116 112 110 107 105 104
43 R 132 130 131 129 127 126 122
44 B 136 135 132 130 128 126 124 122 120 118 119
45 R 132 130 128 126 120 118 116 114 116 118 118
46 R 136 132 130 128 126 125 126
47 R 132 130 128 126 124 122 120 118
48 R 128 126 124 122 120 118 120
49 B 142 140 138 136 134 130 128 127 126
50 B 126 124 122 120 118 119 117 116
51 R 130 128 126 124 122 120 121 119
52 R 140 138 138 136 134 132 130 128 130 128
53 R 132 130 128 126 124 120 118 114 114 110 108
54 B 126 124 124 120 118 116 114 110
55 R 130 126 125 122 120 118 116 114 116
56 R 138 136 132 130 128 126 122
57 R 130 128 126 125 124 120 118 116 116 114 116 115 114
58 R 136 136 132 133 130 128 125
59 R 138 134 132 130 128 124 122 124
60 R 136 132 130 128 126 122
MASTER CHART - INTRA OPERATIVE HEART RATE - TIME (MIN)
S. No. Grp BASE Bef.Inc 5 10 15 20 25 30 35 40 45 50 55 60
1 B 106/62 100/60 98/58 96/56 98/56 98/58 100/60
2 B 102/58 100/56 98/56 96/56 96/58 98/58 100/60
3 B 100/58 98/56 96/56 98/56 98/58 100/58
4 R 106/60 102/58 102/60 100/58 102/56 100/58 98/60 100/58
5 R 108/60 104/58 102/58 100/58 102/58 104/58 102/56
6 B 98/62 98/60 96/58 96/56 98/56 98/58 98/56 98/58 100/58
7 B 100/58 98/58 96/56 98/56 98/58 98/56 100/56 100/58 98/60 100/58
8 R 110/66 108/62 106/60 104/58 102/56 102/58 102/54 98/56 100/58 100/60 102/58 100/62
9 R 102/66 100/62 96/60 96/56 96/56 98/56
10 B 100/58 98/58 96/56 98/56 98/58 98/60
11 B 102/60 100/58 98/56 96/56 98/56 98/58 100/60
12 B 98/58 96/56 96/54 96/56 98/58 100/58
13 R 100/62 98/58 98/56 96/54 96/56 98/56
14 B 102/62 100/60 98/58 98/56 98/56 98/58 100/60
15 R 104/62 96/60 98/58 98/56 98/58 96/58 100/60 100/58
16 R 106/62 100/60 98/58 96/58 96/56 98/58 102/60 100/62 106/58 104/62 106/60 104/58102/60
17 R 100/58 98/56 96/58 96/54 96/56 96/58 100/58
18 B 100/56 98/56 96/54 96/56 98/56 98/58 98/56 96/58 98/56 98/58
19 R 102/62 98/60 100/58 98/56 98/58 96/56 96/58
20 B 106/68 104/64 102/62 100/60 98/58 98/60 98/58 100/60 100/62
21 B 102/64 100/60 98/58 98/56 98/56 98/58 98/56 98/58 100/56 100/58 100/56 102/56100/58102/60
22 B 102/58 100/56 98/56 96/56 98/56 98/58 100/58
23 B 106/64 104/62 102/60 100/58 100/60 100/58 100/60
24 B 108/66 106/62 104/60 102/58 100/58 100/60 102/58 102/60
25 B 100/58 98/56 96/54 96/56 98/56 98/58 100/58
26 B 102/64 100/62 98/60 96/58 98/58 98/60 100/58 102/60
27 R 104/60 100/58 102/62 100/58 98/56 96/58 100/56 98/60
28 R 102/66 102/62 96/60 96/58 98/56 98/58 100/60
29 B 102/66 100/64 98/62 96/60 96/58 98/58 98/60 98/58 98/60 100/58 100/62
30 R 106/66 100/64 94/58 96/56 96/58 98/58 98/60 96/60 96/58 98/60 100/58 102/60
31 R 108/70 104/66 96/58 96/56 94/58 96/58 100/58 98/66
32 B 110/68 104/64 102/62 100/60 98/58 98/56 98/58 100/58 100/60 102/60
33 R 100/62 100/62 98/60 98/60 96/58 96/60 98/58 98/62 96/60 98/58 96/60
34 B 102/62 98/60 96/58 96/56 96/54 96/56 96/58 98/58 100/58 100/60
35 R 106/64 100/60 96/58 96/58 96/58 98/58 102/60 104/62
36 B 102/62 102/60 100/58 98/56 96/56 98/56 100/58
37 B 110/64 104/64 102/62 100/60 98/58 98/56 98/58 100/58 100/60 102/60 102/62
38 B 106/62 104/62 102/60 100/58 98/58 100/58 100/60
39 B 108/66 106/64 104/62 100/60 98/58 100/58 102/58 100/60 102/60 102/58
40 R 102/62 100/60 98/58 96/56 98/56 98/58
41 B 106/62 102/60 100/58 98/56 98/58 100/58 98/58 100/58 102/58 102/60 102/62
42 B 106/62 102/60 100/58 98/56 98/58 100/58 100/60 100/58 100/60
43 R 100/60 98/60 98/58 96/56 98/56 100/56 100/60
44 B 100/62 98/60 96/58 96/56 98/56 96/56 98/56 98/58 100/58 100/60 102/60
45 R 106/62 100/58 102/60 100/58 100/58 102/58 104/58 100/58 100/60 102/58 104/62
46 R 102/60 102/56 100/58 96/58 98/56 98/58 96/60
47 R 104/62 98/60 90/58 94/56 96/56 98/56 100/58 102/58
48 R 102/64 100/60 98/58 98/56 98/58 100/58
49 B 100/62 98/60 96/58 96/56 98/56 98/58 100/58 100/60 102/58
50 B 102/64 100/62 98/60 96/58 98/58 100/58 100/60 100/62
51 R 102/60 98/62 96/58 96/60 98/58 100/58
52 R 100/62 96/60 96/58 94/58 96/56 98/58 100/58 96/62 98/60
53 R 104/60 102/60 102/58 100/56 100/58 100/58 96/58 98/58 102/62 102/60 102/62
54 B 106/62 102/60 100/58 98/56 98/58 100/58 100/60 102/60
55 R 102/62 100/60 96/58 96/58 98/56 100/58 100/60 102/60
56 R 98/58 102/62 100/62 98/60 96/58 100/58 102/60
57 R 102/64 100/60 102/58 100/58 100/56 100/58 102/58 102/60 104/58 100/56 102/62 100/58102/62
58 R 100/60 102/58 100/56 98/56 98/58 98/60 98/60
59 R 102/62 100/60 98/58 98/56 98/58 100/56 100/58
60 R 106/62 102/60 100/58 98/58 98/56 100/58
MASTER CHART - INTRA OPERATIVE BLOOD PRESSURE  -TIME (MIN)
S. No.Grp BASE
Bef.
Inc 5 10 15 20 25 30 35 40 45 50 55 60
D.O.S
(min)
1 B 99 100 100 100 100 100 100 100 100 25
2 B 99 100 100 99 99 99 100 25
3 B 100 100 100 100 99 99 20
4 R 99 100 100 100 100 100 100 100 30
5 R 100 99 100 99 100 100 99 25
6 B 99 100 100 100 99 99 99 100 100 35
7 B 99 100 100 99 99 100 100 99 100 100 40
8 R 99 100 100 100 100 100 100 100 100 100 100 45
9 R 99 100 100 100 100 99 20
10 B 99 100 100 100 100 99 20
11 B 99 100 99 100 100 100 100 25
12 B 100 99 100 99 100 100 20
13 R 100 99 100 99 100 100 100 100 30
14 B 100 100 99 100 99 100 99 25
15 R 99 100 100 100 100 100 100 100 30
16 R 99 100 99 99 99 99 99 99 100 100 100 99 50
17 R 100 100 100 100 100 100 100 100 100 35
18 B 99 100 99 100 100 100 100 100 99 99 40
19 R 100 99 100 100 100 99 99 25
20 B 99 100 100 100 100 100 99 100 99 35
21 B 99 100 99 100 99 100 100 100 100 99 100 100 100 100 60
22 B 100 100 100 100 100 99 100 25
23 B 99 100 100 100 99 100 99 25
24 B 100 100 100 100 99 100 100 99 30
25 B 100 99 100 99 99 100 99 25
26 B 99 100 100 100 100 99 100 99 30
27 R 100 99 100 100 100 99 100 100 30
28 R 100 100 100 100 100 100 100 25
29 B 100 99 100 100 100 100 100 99 100 100 99 45
30 R 100 100 99 100 99 100 100 99 100 100 100 100 50
31 R 100 100 100 100 100 100 100 99 30
32 B 100 100 100 99 100 99 100 99 100 99 40
33 R 99 100 100 99 100 100 99 99 100 100 100 100 50
34 B 99 100 100 100 99 100 99 100 100 100 40
35 R 100 100 100 100 99 100 99 100 30
36 B 100 100 100 99 100 99 99 25
37 B 99 100 99 100 99 100 100 100 100 100 100 45
38 B 100 100 100 99 100 99 100 25
39 B 99 100 100 100 100 100 100 100 100 100 40
40 R 99 100 99 100 99 99 20
41 B 100 99 100 100 100 99 100 100 99 100 99 45
42 B 99 100 100 100 100 100 100 100 99 35
43 R 99 100 100 100 100 100 100 25
44 B 100 100 100 100 100 99 100 99 100 100 100 45
45 R 99 100 100 99 100 100 100 100 99 100 100 45
46 R 100 99 100 100 100 99 99 25
47 R 100 100 100 100 100 100 99 100 30
48 R 99 100 100 100 100 100 100 25
49 B 99 100 100 99 100 100 100 100 100 35
50 B 99 100 100 99 100 100 100 99 30
51 R 99 100 100 100 99 99 100 99 30
52 R 99 100 100 100 100 100 99 100 100 99 40
53 R 99 100 100 100 100 100 100 100 99 100 99 45
54 B 99 100 100 100 100 100 100 100 30
55 R 100 100 99 100 99 100 100 99 35
56 R 99 100 100 99 100 99 100 25
57 R 99 100 100 99 100 100 100 100 100 100 100 100 99 55
58 R 100 100 99 100 100 99 99 25
59 R 99 100 99 100 100 100 100 100 30
60 R 99 100 100 99 100 99 20
MASTER  CHART -  INTRA OPERATIVE 02  SATURATION  - TIME (MIN)
S.
No. Grp 0 15 30 45 60 75 90 105 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600
1 B 0 0 0 0 1 1 1 2 2 2 3 3 3 3 3 3 3 3 4 3 4 5 5 5 5
2 B 0 0 0 0 0 0 0 1 1 1 1 2 2 2 2 2 3 4 4 5 5 5 4 5 5
3 B 0 0 0 0 0 0 0 1 1 2 2 2 2 2 2 2 2 3 4 4 5 5 6 5 5
4 R 0 0 0 0 1 1 1 1 2 2 2 2 2 3 3 3 3 3 4 3 4 5 4 4 4
5 R 0 0 0 0 0 1 1 1 1 2 2 2 3 3 3 3 4 3 4 5 4 5 4 5 4
6 B 0 0 0 0 2 2 2 2 2 2 3 3 3 3 4 4 4 4 5 5 5 5 5 5 5
7 B 0 0 0 0 0 1 1 1 2 2 3 3 4 3 4 4 4 5 5 5 5 5 5 5 5
8 R 0 0 0 0 0 1 1 1 1 2 2 2 3 3 4 3 4 5 4 5 4 4 5 4 4
9 R 0 0 0 0 1 1 1 1 2 2 2 3 3 4 3 4 5 4 5 4 5 6 5 4 4
10 B 0 0 0 0 1 1 1 2 2 2 3 3 3 4 3 4 4 4 5 5 5 5 5 5 5
11 B 0 0 0 0 1 1 2 2 2 2 3 3 3 4 5 4 5 4 5 5 5 6 5 5 5
12 B 0 0 0 0 1 1 1 2 3 3 4 3 5 4 5 5 5 4 6 5 5 5 5 5 5
13 R 0 0 0 0 1 1 1 2 2 2 3 3 3 3 3 4 4 5 4 5 4 5 4 4 4
14 B 0 0 0 0 2 2 2 3 3 3 3 3 4 5 5 4 5 6 5 6 5 5 5 5 6
15 R 0 0 0 0 1 1 1 2 2 2 2 3 3 3 3 4 4 3 4 4 4 4 5 4 5
16 R 0 0 0 1 1 1 2 2 2 2 3 3 3 3 4 3 4 4 5 5 4 5 4 5 4
17 R 0 0 0 0 1 1 1 1 2 2 2 2 3 3 3 3 4 3 4 3 4 5 4 5 4
18 B 0 0 0 0 1 2 2 2 3 3 3 3 4 5 5 4 5 5 6 5 5 5 5 5 5
19 R 0 0 0 0 1 1 1 2 2 2 3 4 3 4 4 5 4 4 5 4 4 5 4 4 4
20 B 0 0 0 0 0 2 2 2 2 2 3 3 3 4 4 5 4 4 3 4 5 5 4 4 4
21 B 0 0 0 0 1 1 2 2 2 2 3 3 3 3 3 4 3 4 4 3 4 4 5 4 4
22 B 0 0 0 0 0 2 2 2 2 2 3 3 3 3 3 4 3 4 4 5 4 4 5 4 5
23 B 0 0 0 0 0 1 1 2 2 2 3 3 3 4 3 4 5 4 5 5 4 5 5 5 4
24 B 0 0 0 0 1 1 1 2 2 2 3 3 3 3 4 3 4 5 5 5 4 5 3 4 5
25 B 0 0 0 0 0 1 1 1 2 2 3 3 3 3 3 4 5 5 4 5 5 4 5 5 5
26 B 0 0 0 0 0 1 1 1 2 2 2 2 3 3 3 4 3 5 4 5 4 3 4 5 5
27 R 0 0 0 0 1 1 1 1 2 2 3 3 4 3 4 3 4 5 4 5 4 5 4 4 4
28 R 0 0 0 0 1 1 1 1 2 2 3 3 3 3 3 4 3 4 5 4 5 4 5 5 5
29 B 0 0 0 0 0 0 1 1 2 2 3 3 3 3 4 4 4 5 5 5 4 5 4 5 4
30 R 0 0 0 1 1 1 1 2 2 2 2 3 3 3 4 3 4 4 4 5 4 5 4 4 4
31 R 0 0 0 0 1 1 1 1 2 2 2 3 3 3 3 4 3 4 4 5 4 5 4 4 5
32 B 0 0 0 0 0 1 1 2 2 2 3 3 3 3 4 3 5 4 5 5 4 5 4 5 4
33 R 0 0 0 0 1 1 1 1 2 2 2 3 3 3 4 3 4 4 4 5 4 5 4 5 5
34 B 0 0 0 0 0 0 0 1 1 1 1 2 2 2 3 3 4 3 5 4 4 3 4 5 4
35 R 0 0 0 0 1 1 1 1 2 2 2 3 3 4 3 4 5 4 4 4 4 4 5 4 5
36 B 0 0 0 0 1 1 1 1 2 2 2 3 3 3 4 3 4 4 4 4 5 4 5 4 5
37 B 0 0 0 0 0 0 1 1 1 2 2 2 3 4 3 4 5 4 3 4 5 4 5 4 4
38 B 0 0 0 0 1 1 1 2 2 2 2 3 3 3 3 4 4 4 3 4 3 4 5 4 3
39 B 0 0 0 0 1 1 1 2 2 2 3 3 3 3 3 4 3 4 4 5 4 5 4 4 5
40 R 0 0 0 0 1 1 1 1 2 2 2 3 3 4 3 4 4 5 4 5 4 5 4 4 4
41 B 0 0 0 0 1 1 2 2 2 3 3 3 3 4 3 4 3 4 5 4 5 4 4 5 4
42 B 0 0 0 0 1 1 1 2 2 2 2 3 3 3 4 4 3 4 5 4 5 4 5 4 4
43 R 0 0 0 0 1 1 1 1 2 2 2 3 3 3 4 4 3 4 5 4 5 4 4 4 4
44 B 0 0 0 0 2 2 2 2 3 3 3 3 4 3 4 3 4 5 4 4 5 4 5 4 4
45 R 0 0 0 0 1 1 1 2 2 2 2 3 3 3 4 3 4 5 4 5 4 5 4 4 4
46 R 0 0 0 0 1 1 1 1 2 2 3 3 4 4 3 4 5 4 5 4 4 5 4 5 4
47 R 0 0 0 0 1 1 1 1 2 2 2 3 3 3 4 3 4 5 5 4 5 5 4 5 4
48 R 0 0 0 0 1 1 1 2 2 2 3 3 3 4 3 4 5 4 5 4 5 4 4 4 5
49 B 0 0 0 0 1 1 2 2 2 2 3 3 3 3 4 3 4 3 4 5 4 5 4 5 4
50 B 0 0 0 0 1 1 1 2 2 2 2 3 3 3 3 4 3 4 3 4 5 4 5 4 4
51 R 0 0 0 0 1 1 1 2 2 2 2 3 3 3 3 4 4 5 3 4 5 4 5 4 4
52 R 0 0 0 0 1 1 1 1 2 2 2 3 3 3 4 3 4 5 4 5 4 5 4 5 4
53 R 0 0 0 0 1 1 1 1 2 2 3 3 4 3 4 5 4 5 4 5 4 4 5 4 5
54 B 0 0 0 0 1 1 1 1 2 2 2 3 3 3 3 4 3 4 4 5 4 5 4 4 4
55 R 0 0 0 0 1 1 1 2 2 2 3 3 3 3 4 3 4 5 4 5 4 5 5 5 5
56 R 0 0 0 0 1 1 1 2 2 3 3 4 3 4 5 4 5 4 5 4 5 4 5 4 4
57 R 0 0 0 0 1 1 1 2 2 2 3 3 3 3 4 3 4 5 4 5 4 5 4 5 5
58 R 0 0 0 0 1 1 1 2 2 2 3 3 4 3 4 5 4 5 4 5 5 4 5 5 5
59 R 0 0 0 1 1 1 2 2 2 2 3 3 3 3 4 3 4 5 4 5 4 5 5 5 5
60 R 0 0 0 0 1 1 1 2 2 2 2 3 3 3 3 4 3 4 5 4 5 4 5 5 5
MASTER CHART - HANNALLAH  PAIN SCALE - TIME (MIN)
S.
No. Grp 0 15 30 45 60 75 90 105 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600
1 B 3 3 4 5 6 6 6 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
2 B 2 2 3 5 5 5 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
3 B 2 2 2 2 3 4 5 7 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
4 R 3 4 4 6 7 7 8 9 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
5 R 2 3 4 5 5 5 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
6 B 2 2 2 3 3 3 5 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
7 B 2 2 2 3 3 4 5 7 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
8 R 2 4 4 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
9 R 3 4 4 5 5 7 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
10 B 2 2 2 3 4 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
11 B 2 2 2 3 5 5 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
12 B 2 2 2 3 4 5 5 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
13 R 2 2 3 3 3 5 5 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
14 B 2 2 3 3 5 7 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
15 R 2 3 3 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
16 R 3 4 4 4 5 7 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
17 R 2 2 3 3 3 5 5 7 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
18 B 2 2 3 3 5 6 8 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
19 R 2 3 4 5 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
20 B 2 2 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
21 B 2 2 3 3 5 5 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
22 B 2 2 3 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
23 B 2 2 3 3 3 5 7 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
24 B 2 3 3 5 5 6 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
25 B 2 2 2 3 3 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
26 B 2 2 3 3 5 5 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
27 R 2 3 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
28 R 3 3 5 5 7 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
29 B 2 2 2 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
30 R 2 2 2 3 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
31 R 3 3 3 3 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
32 B 2 2 3 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
33 R 3 3 3 4 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
34 B 2 2 3 3 5 5 7 8 9 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10
35 R 2 2 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
36 B 2 2 3 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
37 B 2 2 2 3 3 5 6 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
38 B 2 2 3 3 5 5 7 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
39 B 2 3 3 5 5 7 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
40 R 2 2 3 3 5 5 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
41 B 2 2 2 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
42 B 2 2 2 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
43 R 3 3 3 4 4 5 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
44 B 2 2 2 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
45 R 2 2 2 3 5 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
46 R 2 2 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
47 R 2 2 3 3 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
48 R 2 2 2 4 5 7 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
49 B 2 2 3 3 4 5 5 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
50 B 2 2 3 3 5 5 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
51 R 2 2 3 5 5 5 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
52 R 3 3 4 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
53 R 2 2 3 3 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
54 B 2 2 3 3 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
55 R 2 3 4 4 5 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
56 R 2 3 3 4 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
57 R 2 3 3 5 5 7 8 9 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
58 R 2 3 3 5 5 7 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
59 R 3 3 3 5 5 5 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
60 R 3 3 5 5 5 8 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
MASTER CHART - MOTOR POWER SCALE -TIME (MIN)
S.
No. Group
T.F.A.
(min)
 T.M.R.
(min)
T.S.R.
(min)
T.F.M
(min)
1 B 460 150 120 420
2 B 425 150 120 450
3 B 475 150 120 375
4 R 455 150 120 400
5 R 395 120 105 375
6 B 330 120 105 475
7 B 280 150 105 420
8 R 330 105 105
9 R 315 105 105 480
10 B 310 120 105 450
11 B 330 120 105 475
12 B 255 105 105 510
13 R 380 120 105 495
14 B 275 105 105 450
15 R 360 105 105 425
16 R 335 105 105
17 R 390 120 105 500
18 B 280 105 105 420
19 R 245 105 105 470
20 B 305 105 105 500
21 B 390 150 120
22 B 370 120 120 375
23 B 330 120 105 420
24 B 340 120 105 450
25 B 360 150 120 480
26 B 365 150 105 420
27 R 290 105 105 390
28 R 375 120 105 420
29 B 355 120 105 450
30 R 370 120 120
31 R 365 120 105 375
32 B 335 120 105 480
33 R 335 120 105
34 B 400 150 120 435
35 R 310 105 105 400
36 B 335 120 105 490
37 B 310 120 105 420
38 B 380 150 120 440
39 B 385 150 105 435
40 R 305 105 105 400
41 B 315 120 105
42 B 335 120 120
43 R 340 120 105 360
44 B 305 105 105
45 R 355 105 105 420
46 R 290 105 105 440
47 R 350 120 120 420
48 R 305 105 105 450
49 B 335 120 105 450
50 B 370 150 120 480
51 R 385 120 120 420
52 R 335 105 105 475
53 R 290 105 105
54 B 360 120 105 490
55 R 355 120 105 520
56 R 255 105 105 475
57 R 355 120 105
58 R 285 105 105 480
59 R 340 120 105 500
60 R 370 120 120 475
MASTER CHART-POST OPERATIVE  ANALGESIC REQUIREMENT
S.
No. Grp 0 30 60 90 120 150 180 240 300 360 420 480 540 600
1 B 120 116 110 106 100 102 98 104 98 99 103 107 109 110
2 B 120 115 106 102 98 96 97 97 98 103 103 107 107 109
3 B 118 114 110 107 103 102 101 97 98 103 105 106 107 110
4 R 118 115 112 108 102 100 100 100 104 109 113 120 118 122
5 R 116 116 112 108 103 100 99 96 99 104 104 106 105 112
6 B 117 112 109 105 102 101 100 97 96 100 103 107 108 112
7 B 118 113 110 107 104 102 100 97 98 103 104 108 110 110
8 R 110 110 106 100 97 96 97 97 99 103 107 118 118 120
9 R 116 110 106 102 98 96 96 96 100 105 105 106 110 114
10 B 112 107 104 101 97 98 99 98 97 102 106 108 109 112
11 B 110 106 103 100 97 95 94 98 99 103 102 107 107 110
12 B 120 116 113 108 105 102 100 97 98 104 103 107 107 108
13 R 114 110 106 108 103 101 100 97 97 102 102 108 112 116
14 B 118 112 106 103 98 95 96 97 98 99 101 105 106 106
15 R 115 110 108 108 102 99 97 96 100 104 104 112 114 120
16 R 116 112 106 102 97 95 97 95 98 102 101 98 106 105
17 R 114 110 108 107 102 100 98 97 101 105 105 104 108 110
18 B 122 116 112 108 104 102 101 100 99 99 103 105 107 108
19 R 128 120 116 110 105 103 101 97 102 104 104 122 118 115
20 B 112 107 103 100 98 96 98 97 97 101 100 101 102 106
21 B 112 107 103 99 96 98 96 97 98 100 101 104 106 107
22 B 113 108 103 100 98 96 98 99 98 101 99 104 106 105
23 B 113 108 104 102 98 96 98 97 100 103 107 108 107 108
24 B 117 112 108 104 101 99 97 96 101 105 106 105 109 114
25 B 126 117 110 104 100 106 103 101 105 110 108 108 107 110
26 B 112 105 101 98 98 99 101 96 101 101 103 107 107 108
27 R 120 112 104 100 96 95 97 97 97 101 99 104 102 106
28 R 112 108 102 101 96 96 95 97 99 99 103 101 99 104
29 B 114 108 105 101 97 98 96 97 101 105 104 107 108 108
30 R 116 110 106 102 97 95 97 94 98 102 101 103 103 108
31 R 108 104 100 101 96 94 96 95 97 99 102 104 105 106
32 B 111 105 101 97 96 95 97 98 99 102 101 105 107 108
33 R 120 114 108 100 96 95 96 96 96 100 99 103 102 105
34 B 117 110 105 101 97 98 96 98 99 99 104 105 106 110
35 R 120 114 110 105 100 98 99 99 99 101 104 103 107 108
36 B 122 116 110 106 102 100 98 99 100 101 103 104 105 109
37 B 108 103 100 98 95 97 96 97 101 100 104 108 110 112
38 B 112 108 104 100 96 94 97 97 100 101 105 106 105 108
39 B 110 103 99 96 95 96 98 99 103 98 103 107 105 106
40 R 122 115 112 104 99 97 99 96 100 100 100 107 108 110
41 B 113 109 104 101 97 96 98 99 98 99 104 106 107 110
42 B 101 96 93 97 98 96 99 98 99 102 103 107 104 104
43 R 120 115 112 107 102 100 98 98 102 99 99 102 106 108
44 B 118 113 108 104 99 100 97 98 99 103 105 106 106 110
45 R 110 104 98 97 95 93 95 96 99 100 104 105 106 110
46 R 124 119 115 110 105 103 102 101 100 103 107 108 112 115
47 R 115 110 106 105 101 99 100 102 102 106 107 113 113 117
48 R 116 112 107 103 98 97 99 100 99 103 103 107 111 115
49 B 122 117 112 107 104 102 100 97 98 103 104 105 108 112
50 B 112 106 102 98 97 96 98 98 99 100 104 105 109 108
51 R 116 110 105 103 99 97 99 98 98 102 103 107 109 112
52 R 122 116 110 106 101 100 101 100 101 104 106 105 110 115
53 R 106 101 97 94 96 95 97 98 100 105 106 110 109 112
54 B 107 102 97 95 95 98 99 98 95 102 103 107 108 109
55 R 112 106 100 99 95 93 95 96 99 103 105 109 112 114
56 R 122 117 113 110 104 102 100 101 100 105 109 113 113 118
57 R 114 105 98 97 94 95 95 96 97 102 104 108 109 113
58 R 120 116 110 104 97 95 97 96 101 102 101 108 112 114
59 R 120 115 110 105 99 97 99 99 100 100 104 105 109 110
60 R 118 112 108 103 98 98 98 95 97 103 104 104 105 107
MASTER CHART - POST OPERATIVE  PULSE RATE - TIME (MIN)
S.
No. Grp 0 30 60 90 120 150 180 240 300 360 420 480 540 600
1 B 100 100 100 100 100 98 102 98 102 102 102 102 104 104
2 B 98 98 98 98 98 96 100 96 98 100 100 100 104 104
3 B 98 98 98 98 100 98 96 100 100 100 104 106 104 104
4 R 100 100 98 100 100 102 100 100 102 106 102 102 104 102
5 R 102 100 100 104 102 104 102 100 104 102 104 108 104 108
6 B 96 96 96 96 96 98 94 94 98 102 98 98 102 102
7 B 98 98 98 98 98 96 100 96 100 102 98 102 102 102
8 R 98 98 98 102 100 98 100 98 102 102 106 108 104 106
9 R 100 100 98 98 100 100 102 98 98 102 102 106 106 106
10 B 98 98 98 98 94 96 98 98 98 100 100 100 104 102
11 B 98 94 98 98 98 100 98 98 98 102 102 98 102 106
12 B 96 96 96 96 100 98 96 100 100 100 100 104 104 106
13 R 98 100 100 100 100 98 100 100 98 102 106 106 108 106
14 B 98 96 100 100 100 102 100 96 100 100 104 104 104 104
15 R 100 100 100 100 100 98 100 98 100 100 104 108 104 106
16 R 100 100 96 100 100 102 100 102 106 104 106 106 106 106
17 R 98 94 98 98 96 98 96 100 98 100 100 102 102 106
18 B 98 98 98 98 98 100 98 98 102 102 104 102 106 104
19 R 100 100 98 102 98 100 98 102 98 98 102 102 106 106
20 B 98 98 98 102 102 100 98 102 98 102 106 106 104 104
21 B 98 98 98 98 98 96 100 96 100 100 100 102 102 104
22 B 98 98 98 98 98 100 98 98 100 100 100 104 104 108
23 B 100 100 100 100 100 102 104 104 104 104 104 104 104 108
24 B 100 100 104 102 102 100 102 102 98 102 102 106 104 106
25 B 98 98 98 94 98 96 98 98 98 98 102 102 102 104
26 B 100 96 100 100 104 102 100 104 100 104 104 104 104 108
27 R 98 102 98 100 100 98 100 100 104 102 106 106 106 108
28 R 98 98 98 98 98 100 98 98 100 100 104 104 104 106
29 B 98 98 98 98 98 100 98 98 98 98 102 102 102 106
30 R 98 98 98 102 98 100 102 98 102 98 102 102 106 106
31 R 98 102 98 102 102 100 104 100 104 102 102 106 106 108
32 B 100 100 102 98 98 100 102 102 102 102 106 108 108 108
33 R 98 98 98 98 96 98 100 98 98 100 98 98 98 102
34 B 98 98 94 98 98 96 98 98 98 102 102 102 102 106
35 R 102 102 98 102 98 100 102 100 98 100 100 102 106 104
36 B 98 98 98 98 98 100 98 98 98 102 102 102 106 104
37 B 100 100 98 102 98 100 102 98 102 98 102 104 106 106
38 B 98 98 98 102 100 102 98 102 98 102 106 106 106 110
39 B 100 100 100 100 100 102 100 100 100 104 104 104 108 108
40 R 98 98 98 98 98 96 98 98 102 98 102 102 102 106
41 B 98 98 98 102 98 96 100 96 100 96 100 100 104 108
42 B 100 100 100 96 100 102 100 100 100 100 102 106 106 106
43 R 98 98 94 98 94 98 96 96 98 102 102 98 102 104
44 B 98 98 98 98 98 96 98 98 98 102 102 104 102 106
45 R 98 98 102 98 102 98 100 98 102 102 102 106 106 108
46 R 98 98 98 94 98 96 98 98 98 102 106 110 106 110
47 R 100 100 100 100 98 100 98 98 100 100 104 104 104 108
48 R 98 98 98 98 100 98 100 96 98 100 100 100 104 108
49 B 98 98 98 98 98 96 98 98 98 98 102 102 102 106
50 B 98 98 98 98 98 100 98 98 102 102 102 104 108 110
51 R 98 100 100 100 96 98 100 100 96 100 100 104 108 106
52 R 96 96 96 100 96 98 100 96 102 106 104 106 108 110
53 R 98 98 98 98 100 98 96 98 100 100 104 102 102 106
54 B 100 100 100 100 100 104 102 98 102 102 106 108 108 110
55 R 100 98 98 98 98 96 98 100 100 104 100 104 104 106
56 R 96 96 96 100 96 100 98 102 98 102 104 100 104 104
57 R 100 100 96 100 100 102 102 102 102 106 106 106 106 108
58 R 98 98 98 98 96 98 100 96 102 102 102 104 106 106
59 R 98 98 98 98 98 100 98 102 98 102 102 104 104 104
60 R 98 98 98 102 102 100 98 98 104 102 106 106 106 106
MASTER CHART - POST-OPERATIVE SYSTOLIC BLOOD PRESSURE - TIME (MIN)
S. No. Group 0 30 60 90 120 150 180 240 300 360 420 480 540 600
1 B 99 100 100 100 99 100 100 100 100 99 99 99 99 99
2 B 100 100 100 100 99 99 99 99 100 99 99 99 99 100
3 B 100 99 99 100 100 100 100 100 99 100 100 100 99 100
4 R 100 99 99 99 99 99 99 99 99 100 99 99 99 99
5 R 100 100 100 100 99 99 98 98 99 99 99 99 99 100
6 B 100 100 100 100 100 99 100 100 99 99 99 99 99 99
7 B 100 100 100 100 100 99 100 99 99 99 99 99 99 99
8 R 100 100 100 100 100 99 99 99 99 99 99 99 100 100
9 R 100 99 100 99 99 100 100 100 100 100 100 100 100 100
10 B 99 100 100 100 100 99 100 100 100 99 99 99 100 100
11 B 100 100 100 100 100 100 100 99 99 100 100 99 100 100
12 B 99 100 100 99 99 99 99 99 99 99 100 99 100 100
13 R 100 99 99 99 99 99 99 99 99 100 99 99 99 99
14 B 100 100 100 99 99 99 99 99 99 100 100 99 100 100
15 R 100 100 100 100 99 99 98 98 99 99 99 99 99 100
16 R 100 100 100 100 100 99 99 99 99 99 99 99 100 100
17 R 99 100 100 99 99 99 99 99 100 99 99 99 99 99
18 B 100 100 100 100 99 99 99 99 99 100 100 100 100 99
19 R 99 99 100 100 99 100 100 99 99 99 100 99 100 100
20 B 99 99 99 99 99 99 99 99 100 100 100 99 100 99
21 B 100 100 100 100 99 99 99 100 99 99 99 99 99 99
22 B 99 99 99 99 99 99 99 100 100 99 99 100 100 100
23 B 100 100 100 99 99 99 99 100 100 100 100 99 100 99
24 B 100 99 99 99 100 100 99 99 99 99 99 99 100 100
25 B 100 99 100 100 100 100 100 99 99 99 99 99 100 99
26 B 99 99 99 99 99 99 99 99 100 99 99 99 99 99
27 R 100 100 99 100 100 99 100 99 99 100 100 99 100 100
28 R 100 100 100 100 100 100 100 99 99 99 99 99 99 99
29 B 100 100 100 100 100 100 100 100 100 100 100 99 99 99
30 R 100 100 100 100 100 100 100 100 100 100 100 99 100 100
31 R 99 100 100 100 100 100 100 99 100 100 100 99 99 100
32 B 99 100 100 100 99 99 99 99 100 100 100 100 100 100
33 R 100 100 100 99 99 99 99 99 100 100 100 100 100 100
34 B 100 100 100 100 100 99 99 99 100 100 100 99 100 100
35 R 99 99 99 99 99 100 99 99 99 99 99 99 99 100
36 B 100 100 99 99 99 99 99 100 100 99 99 99 100 100
37 B 100 100 100 100 99 99 99 99 99 100 100 100 100 100
38 B 100 100 100 100 99 99 99 100 100 100 99 99 99 99
39 B 99 100 100 100 99 99 99 99 99 99 100 99 99 100
40 R 99 99 99 99 100 100 100 100 100 100 100 100 100 100
41 B 100 100 100 99 99 99 99 99 99 99 99 99 100 100
42 B 100 100 100 99 99 99 99 99 100 100 100 100 100 100
43 R 100 99 100 100 99 99 100 100 100 99 99 99 99 99
44 B 99 99 99 99 99 99 99 99 100 100 100 99 100 100
45 R 100 99 99 99 100 99 100 99 100 99 99 99 99 100
46 R 99 99 99 99 99 99 99 100 99 99 99 99 99 99
47 R 100 100 100 99 99 99 99 100 100 100 99 99 100 100
48 R 99 100 100 100 100 99 99 99 99 100 99 99 100 100
49 B 100 100 100 99 99 99 99 100 100 100 100 99 100 100
50 B 100 100 99 99 99 99 99 99 100 100 100 99 100 99
51 R 99 99 99 100 100 99 99 100 99 99 99 99 100 100
52 R 100 100 100 100 100 100 99 100 99 99 100 100 100 100
53 R 99 99 99 99 99 99 99 100 100 100 100 100 100 99
54 B 99 100 99 99 99 100 99 99 99 100 99 100 100 100
55 R 100 100 100 99 99 100 99 99 99 100 100 100 100 100
56 R 100 100 100 100 99 100 99 99 99 100 99 99 99 99
57 R 99 99 99 99 100 100 100 100 99 99 99 99 99 99
58 R 100 100 100 99 99 100 99 99 99 99 99 99 99 100
59 R 99 100 100 100 99 99 99 99 99 99 100 100 99 100
60 R 100 100 100 100 100 99 100 100 100 100 100 100 100 100
MASTER CHART - POST OPERATIVE O2  SATURATION - TIME (MIN)
KEY TO MASTER CHART
Grp -  Group
R -  Ropivacaine
B -  Bupivacaine
M -  Male
F -  Female
Wt -  Weight in kilograms
Ht -  Height in centimeters
Vol. L.A. -  Volume of local anaesthetic
L/R PVSL -  Left/Right Processus Vaginalis Sac Ligation
LIH/RIH -  Left/Right Inguinal Hernia
D.O.S. - Duration of Surgery
Base -  Baseline
Bef. Inc. -  Before Incision
T.F.A. -  Time for First Analgesic drug administration
T.M.R. -  Time for Full Motor Recovery
T.S.R. -  Time for Full Sensory Recovery
T.F.M. -  Time for first Micturition
